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might have dozens of different peptides, and these peptides presum-
ably have overlapping roles with respect to both their antimicrobial and 
innate immune–modulating activities. Thus, it is perhaps unsurpris-
ing that mouse gene knockouts deleting any single peptide have rather 
mild phenotypes, and there are rather few human deficiencies in such 
peptides (and those that exist such as specific granule deficiencies and 
Morbus-Kostmann syndrome are complicated in having other underly-
ing defects).
Host-defense peptides vary substantially even among mammalian 
species7. For example, the cathelicidin peptides mouse CRAMP and 
human LL-37 share only 67% homology, and both species lack the 
substantial variety of cathelicidins in cattle; mice lack neutrophil 
α-defensins that are the most prevalent protein in human neutrophils; 
and cattle completely lack α-defensins in the gut and neutrophils. 
Indeed, there are substantial variations in defensins even among primate 
species8, and these genes are considered to be subject to positive selec-
tion and to be among the most rapidly evolving group of mammalian 
proteins. It seems possible that the rapid coevolution of host-defense 
peptides, of innate immune systems of which they are a part, as well as 
of corresponding microbial counter strategies, including resistance and 
virulence (anti-immunity) strategies, has helped to drive diversity in all 
biological kingdoms4,9.
Some themes among the structures of host-defense peptides do exist, 
however. Mammalian gene structures for the so-called cathelicidins and 
defensins are relatively conserved, and sequences are conserved in their 
precursor (pre-pro) regions. Also within the disulfide bridge–contain-
ing peptides, a three-dimensional structural motif, the so-called gamma 
core, has been conserved throughout 2.5 billion years of evolution, and 
is also present in membrane-active toxins and chemokines, indicating 
possible evolutionary relationships and the potential role of such a motif 
in the effector functions that govern host-pathogen relationships10.
Unlike the β-sheet peptides, the α-helical and extended peptides 
(which include many cathelicidins) tend to be highly flexible in solution, 
and adopt amphipathic structures only upon contact with membranes 
and membrane-mimicking environments. This also holds true for many 
bacterial peptides (termed bacteriocins), even when they contain one or 
two disulfide bonds. Among the bacteriocins of Gram-positive bacte-
ria, there is a particular group, the lantibiotics (lanthionine-containing 
peptide antibiotics), which are characterized by thioether-based 
intramolecular rings resulting from post-translational modifications 
of serine (or threonine) and cysteine residues (for example, nisin and 
mersacidin; Fig. 2)11. Lanthionine rings, some of which represent con-
served binding motifs for recognition of specific targets, create segments 
of defined spatial structures in the peptides12. These ring structures also 
provide stability against proteases, possibly including the antigen-pro-
cessing machinery, because antibodies against highly cross-bridged 
antibiotics, such as mersacidin, are very difficult to obtain.
In addition to ribosomally synthesized antimicrobial peptides, 
microbes also produce peptide antibiotics of broad structural diversity 
using large multifunctional enzymes, the so-called nonribosomal-peptide 
synthetases13. These enzymes have modular structures with each module 
incorporating (and modifying) a specific amino acid, accommodating 
residues in D configurations as well as many other nonprotein amino 
acids, ring formation, glycosylation and acylation. Some prominent 
examples of nonribosomally synthesized peptides include the cationic 
peptides polymyxin B and gramicidin S that are used in the topical treat-
ment of infections, as well as the noncationic glycopeptide vancomycin 
and the lipopeptide daptomycin, which have become important reserve 
antibiotics against multiply resistant Gram-positive bacteria.
Because of the potent antibiotic activity, in the low-nanomolar con-
centration range, of many bacterially derived peptides, it is often taken 
for granted that these peptides are effective weapons in the fight for 
ecological niches. As with many other antibiotic compounds, however, 
experimental data have yet to be obtained showing that, for example, 
lantibiotics are produced in complex ecosystems such as the human 
gastrointestinal tract or skin, or that exogenous producer strains can 
effectively compete with preexisting normal flora because of their abi-
lity to produce an antibiotic compound. In contrast, the knockout of 
a staphylococcal lantibiotic gene cluster resulted in growth attenuation 
in a mouse abscess model14, indicating that there may be additional 
ecological roles for bacteriocins.
Mechanism of action of cationic antimicrobial peptides
Virtually every peptide sequence with a net positive charge and a few 
hydrophobic residues will have antimicrobial activity if assayed in buf-
fer or dilute medium as often used in the literature. It is worth noting, 
however, that the antimicrobial activity of cationic host-defense pep-
tides is antagonized to variable extents by divalent cations like Mg2+ and 
Ca2+ (at physiological concentrations of 1–2 mM), monovalent cations 
such as Na+ and K+ (100 mM), and polyanions such as glycosamino-
glycans (heparin and others) and mucins. Thus, the term antimicrobial 
peptides should be reserved for those peptides that are convincingly 
demonstrated to have an ability to directly kill microbes under such 
physiological conditions.
The cationic and amphiphilic nature of antimicrobial peptides is 
associated with their activity. The overall positive charge ensures accu-
mulation at polyanionic microbial cell surfaces that contain acidic 
polymers, such as lipopolysaccharide, and wall-associated teichoic 
acids in Gram-negative and Gram-positive bacteria, respectively. They 
transit the outer membrane of the former via self-promoted uptake1. 
Subsequently these peptides contact the anionic surface of the cytoplas-
mic membrane and insert in a manner such that they initially straddle 
the interface of the hydrophilic head groups and the fatty acyl chains 
of membrane phospholipids. After insertion into the membrane, anti-
microbial peptides act by either disrupting the physical integrity of the 
bilayer, via membrane thinning, transient poration and/or disruption 
of the barrier function, or translocate across the membrane and act on 
internal targets (Fig. 1).
Several complex and controversial models describe these subsequent 
events, including the reorientation of peptide molecules perpendicular 
Figure 1  Biological roles of host defense peptide. Both direct antimicrobial 
killing and innate immune modulation occur with such peptides although 
certain peptides have one or the other activity preferentially. For a more 
complete outline of direct killing and immune modulation see refs. 1–4.
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to the membrane to form either barrel-stave 
or toroidal channels, the breakdown of mem-
brane integrity as a result of the swamping of 
membrane charge by a ‘carpet’ of peptides at 
the interface, the detergent-like dissolution of 
patches of membrane and the formation of 
peptide-lipid aggregates within the bilayer15. 
Each of these successfully predicts the ability of 
cationic antimicrobial peptides to break down 
the cytoplasmic membrane, but only the toroi-
dal channel and aggregate models explain the 
action of certain peptides on cytoplasmic tar-
gets. Indeed, the action of many peptides can-
not be explained by disruption of membrane 
permeability barriers, as discussed in several 
reviews9,15,16. Other highly charged peptides 
may interfere with the activity of the cell-wall 
lytic enzymes on the outside of the cell17. A 
similar complexity of mechanism also applies 
to the antiviral and anti-fungal action of such 
peptides15.
The development of clinically useable con-
ventional antibiotics has been often biased 
toward the concept of each antibiotic having 
a single primary target and a single mode of 
action, although this may not be entirely cor-
rect18. Nature appears to have chosen a dif-
ferent concept for the evolution of the innate 
host-defense peptides, favoring the design of 
‘dirty’ drugs that disturb many biological func-
tions with modest potency rather than blocking 
a specific high-affinity target9. Peptides have 
been effective for billions of years, so such an 
approach might represent a method of extend-
ing the half-life of these antimicrobials, beyond 
the 1–2 decades enjoyed by most conventional 
antibiotics. There is no question that such pep-
tides will eventually induce resistance9,19, and 
although resistance is clearly more difficult to 
attain than for conventional antibiotics, it has 
been suggested that it might have more severe 
connotations if it led to cross-resistance to innate human antimicrobial 
peptides19. However, several issues mitigate these concerns⎯including 
the fact that to date, (i) all knockout animals lacking host-defense pep-
tides are quite healthy with only modest alteration in susceptibility to 
infection, (ii) the cross-resistance of laboratory-selected mutants to 
other peptides seems to be limited20⎯and the importance of immu-
nomodulatory properties of these peptides, which would not be affected 
by antimicrobial resistance, has been increasingly recognized.
In the case of the lantibiotics, the concept of combining several 
antibiotic activities in one molecule has permitted the achievement 
of unprecedented potencies as demonstrated by, for exa ple, nisin, 
gallidermin and lacticin 3147 (ref. 21). In addition to moderate affin-
ity targets that these peptides use to antagonize a broad spectrum of 
Gram-positive bacteria, they also interact with high-affinity pyro-
phosphate binding sites on the membrane-bound cell wall precursor 
Lipid II (ref. 21), leading to more effective formation of pores and/or 
inhibition of cell wall peptidoglycan biosynthesis. When these activi-
ties operate together, which is usu lly the case with bacteria closely 
related to the producer strain, subnanomolar concentrations are suf-
ficient for killing.
Clinical experience to date
Nature has taught us that cationic peptides have tremendous structural 
diversity and an impressive array of clinically meaningful activities. This 
has provided a huge impetus to the development of new synthetic pep-
tides. Even so, despite nearly two decades of serious design efforts, there 
has been limited success in the clinic22.
To date, four cationic peptides or proteins have advanced into phase 
3 clinical-efficacy trials. These have been indicated for curing or pre-
venting impetigo and diabetic foot ulcers (the frog magainin deriva-
tive MSI-78; Pexiganan), oral mucosaitis (the pig protegrin derivative 
IB-367; Iseganan), sepsis (the human bactericidal permeability protei  
derivative rBPI23; Neuprex) and catheter-associated infections (the 
cattle indolicidin variant CP-226; Omiganan). Only two peptides dem-
onstrated efficacy.
Pexiganan, topically administered to sufferers of diabetic foot ulcer, 
was as effective as oral antibiotic treatment with ofloxacin, leading to a 
clinical cure or improvement in 90% of patients. Even so, the US Food 
and Drug Administrati n (FDA) did not appr ve this drug for medical 
use. In phase 3a clinical trials, Omiganan missed its primary clinical 
target, the prevention of catheter-associated infections, because of a low 
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Abstract
Stable peptidomimetics mimicking natural antimicrobial peptides (AMPs) have emerged as a promising class of potential novel anti-
biotics. In the present study, we aimed at determining whether the antibacterial activity of two a-peptide/b-peptoid peptidomimetics against
a range of bacterial pathogens was affected by conditions mimicking in vivo settings. Their activity was enhanced to an unexpected degree in
the presence of human blood plasma for thirteen pathogenic Gram-positive and Gram-negative bacteria. MIC values typically decreased 2- to
16-fold in the presence of a human plasma concentration that alone did not damage the cell membrane. Hence, MIC and MBC data
collected in these settings appear to represent a more appropriate basis for in vivo experiments preceding clinical trials. In fact, concen-
trations of peptidomimetics and peptide antibiotics (e.g. polymyxin B) required for in vivo treatments might be lower than traditionally
deduced from MICs determined in laboratory media. Thus, antibiotics previously considered too toxic could be developed into usable
last-resort drugs, due to ensuing lowered risk of side effects. In contrast, the activity of the compounds was significantly decreased in
heat-inactivated plasma. We hypothesize that synergistic interactions with complement proteins and/or clotting factors most likely are
involved.
© 2015 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Keywords: Antimicrobial peptide; Peptidomimetics; Antibiotics; Plasma; Synergy
1. Introduction
Bacteria and other microorganisms are becoming resistant
to conventional antibiotics at an alarming rate, and hence,
novel antimicrobial compounds for treatment of infectious
diseases are urgently needed [1]. Several strategies are
being pursued in the search for novel anti-infectives, such
as development of compounds with anti-virulence activity
[2].
Almost all living organisms have an innate frontline de-
fense against microbial infections. Antimicrobial peptides
(AMPs) comprise a diverse group of natural defense com-
pounds that have been isolated from most organisms ranging
from bacteria to humans [3]. Most AMPs are highly cationic
hydrophobic compounds that interact with the bacterial cell
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membrane and cause cell lysis and cell death. AMPs have
been suggested as new antibacterials [4]; however, many
natural AMPs exhibit side effects, e.g. hemolysis or general
cytotoxicity. Also, due to their peptide nature, many AMPs
will rapidly be degraded in vivo by proteases, thereby
diminishing their efficacy [5]. Stable synthetic variants of
AMPs incorporating unnatural residues have been developed
to overcome these shortcomings, and such peptidomimetics
have also been suggested as potential future antibiotics [6,7].
In fact, structural modification may allow optimization of
their bactericidal activity versus cytotoxicty toward human
cells, and hence an improved therapeutic index [8].
Despite the vast plethora of antibacterial compounds being
discovered and chemically synthesized, the transition from
pre-clinical to clinical trial phases still represents a challenge
[9]. In the first evaluation of potential efficacy of novel an-
tibiotics, they are typically tested in laboratory media (e.g.
Mueller-Hinton broth) for minimum inhibitory and minimum
bactericial concentrations (i.e. MICs and MBCs). However,
the actual efficacy in vivo may be different due to in-
teractions with components of the human body [10]. There-
fore, development of laboratory systems that mimic in vivo
conditions will constitute important progress toward a more
efficient selection of candidates for clinical trials. One
obvious approach involves testing the compounds in the
presence of biologically relevant concentrations of blood
matrices and/or at physiological ionic strength. Reduced ac-
tivity of natural and synthetic peptides in serum has often
been raised as a concern [11]. It may, however, be possible to
modify AMPs to overcome this issue or even enhance their
effects in the presence of blood. Indeed, antibacterial pep-
tides derived from or based on human platelets retain their
activity in the presence of human plasma [12]. Also,
Deslouches et al. [10] found that a de novo engineered AMP
rich in arginine (WLBU2) maintained its activity against
Pseudomonas aeruginosa in the presence of both serum and
plasma. In contrast to these synthetic peptides, human cath-
elicidin LL-37 lost its activity in the presence of human
serum as well as in plasma [10]. These findings highlight the
advantages of synthetic analogs over natural AMPs (e.g.
enhanced proteolytic stability in vivo and increased cell
selectivity) [13e15], but also emphasize the need to include
laboratory test methodologies mimicking physiological
conditions.
We recently found that the presence of human blood
plasma unexpectedly increased the activity of a-peptide/b-
peptoid peptidomimetics against Escherichia coli [16];
however, we did not investigate whether this effect is limited
to E. coli or may be extended to other pathogens. The purpose
of the present study was to determine how the antibacterial
effect of these peptidomimetics is influenced by plasma or
serum for a broad range of pathogenic bacteria. Human
plasma proved to potentiate peptidomimetics against all
tested bacteria, and we hypothesized that synergy with
components of the complement system might account for this
observed potentiation. Thus, a major objective became the
testing of this hypothesis.
2. Materials and methods
2.1. Bacterial strains
The effect of human plasma and serum on the antibacterial
activity of peptidomimetics was tested against a panel of
Gram-negative and Gram-positive pathogenic bacteria: E. coli
ATCC 25922, Salmonella typhimurium L354, Serratia mar-
cescens, P. aeruginosa PAO1, Vibrio vulnificus cmcP6, V.
vulnificus DSM 10143, Vibrio parahaemolyticus RimD
D2210633, V. parahaemolyticus ATCC 17802, Staphylococcus
aureus 8325-4, Staphylococcus epidermidis RP62A, S. epi-
dermidis 1457, Listeria monocytogenes EGDe BUG 1600 and
Bacillus cereus ATCC 11778. References to these strains are
reported in Supplemental Table S3.
2.2. Growth conditions and chemicals
The strains were stored at !80 "C and grown overnight at
37 "C (250 rpm) in cation-adjusted Mueller-Hinton II broth
adjusted to pH 7.4 ± 0.2 (MHB, Becton Dickinson, 212322).
The MICs of peptidomimetics were determined in MHB or
MHB supplemented with 1.25% defibrinated horse blood
(REF236999, Statens Serum Institute) to improve growth of B.
cereus and L. monocytogenes [17]. The MBC was determined
by plating from wells with no visible growth on brain heart
infusion agar (BHI, Oxoid, CM1135) containing 1.5% agar
(AppliChem, A7354). Human lyophilized plasma was recon-
stituted in MilliQ water to its original volume of 5 ml to a
concentration of 100%. It was then stored at !20 "C. Human
serum (Sigma Aldrich, H4522) was kept at !20 "C. Both
plasma and serum were purchased as commercially available
products. Plasma from human (Sigma Aldrich, P9523) was
obtained from a pool of 1000e1500 donors, while human
serum derived from human male AB plasma was obtained
from a pool of approximately 200 donors. Ampicillin (Sigma
Aldrich, A9518), gentamicin (Sigma Aldrich, G3632) and
polymyxin B (Sigma Aldrich, P4932) were dissolved in Mil-
liQ water to give stock solutions (10 mg/ml). Citrate solutions
were prepared in MilliQ water with trisodium citrate dihydrate
(Merck Millipore, 106448).
2.3. Peptidomimetics and antimicrobial peptide LL-37
The a-peptide/b-peptoid peptidomimetics 1 and 2 (Fig. 1)
consist of alternating repeats of natural cationic a-amino acids
and synthetic lipophilic b-peptoid residues, and they were
prepared by solid-phase synthesis as previously reported
[8,18]. These compounds were tested for cytotoxicity against
HeLa cells in previous studies [19,20]. Their cytotoxicity (IC50
values) was 32 mM and 96 mM, respectively, while the cyto-
toxicity of closely related compounds towards HeLa cells was
lower (i.e. IC50 values of 316 ± 20 and 228 ± 4 mM,
respectively) [19]. The peptidomimetics exhibited very low
toxicity toward Caco-2 and HUVEC cells (IC50 > 1000 mM)
[19]. The sequence of the human cathelicidin LL-37 is
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-
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CONH2. The compounds were dissolved in MilliQ water to
reach a stock concentration of 10 mg/ml. These stock solutions
were stored at !20 "C.
2.4. Determination of MIC and MBC
MIC was determined by the microdilution broth method
[21] in 96-well non-binding polypropylene microtiter plates
(Thermo Scientific Nunc, 267245) with sterile polystyrene lids
(Sigma Aldrich, CLS3930-100EA). Plates were autoclaved
before use. To determine whether the materials used might
influence the measured activity of the compounds, MIC and
MBC were also tested in plates or vials of different materials.
These included polystyrene plates (Thermo Scientific Nunc,
163320), UV-sterilized polypropylene plates (Thermo Scien-
tific Nunc, 267334; as recommended by Hancock Laboratory
Methods [22]), the above-mentioned non-binding poly-
propylene plates and glass vials (VWR Bie and Berntsen,
2775/378). Stock solutions of peptidomimetics 1 and 2,
ranging from 4096 mg/ml to 32 mg/ml, were prepared in
MilliQ water. Fifty ml of compound solution and 50 ml of the
medium (MHB or MHB supplemented with plasma or serum)
were dispensed into the first well of each row and then twofold
diluted. The influence of native and heat-inactivated plasma
and serum on the antibacterial activity of peptidomimetics and
antibiotics was tested by adding plasma or serum to MHB in
concentrations of 50% and 25%. After addition of peptide
solution and bacterial culture, the resulting exposure concen-
trations were 25% and 12.5%. These tested concentrations of
plasma and serum were based on previous work on E. coli
[16]. However, several strains were unable to grow at these
concentrations of serum and plasma, and therefore, MICs of
serum and plasma for these strains were determined and then
appropriate concentrations of serum and plasma were chosen
based on these MIC values.
Overnight cultures of the strains were diluted in sterile
0.9% NaCl to OD546 ¼ 0.2 (accepted range: 0.195e0.210)
corresponding to approximately 1 $ 108 CFU/ml. This sus-
pension was further diluted 1:100 in MHB and 50 ml of this
culture were inoculated into microtiter plates to reach a final
concentration of 5 $ 105 CFU/ml in a final volume of 100 ml.
Plates were incubated for 20 h at 37 "C. Growth was deter-
mined visually either as turbidity or as formation of a pellet.
MIC was determined to be the lowest concentration of pepti-
domimetics or antibiotics where no growth was observed.
MBC was determined to be the lowest concentration where a
3-log reduction of the original CFU/ml was observed based on
plating from the wells on BHI agar.
2.5. Potentiation of the antibacterial activity of
peptidomimetics by human plasma and serum
The peptidomimetics had more pronounced antibacterial
activity in the presence of plasma and serum (Tables 1e4;
Supplemental Tables S1 and S2), and several experiments
were conducted to determine the mechanism behind this
potentiation. Plasma and serum were heated for 15 min at
56 "C as a non-specific procedure for inactivating the com-
plement [23]. In addition, sodium polyanethole sulfonate
Fig. 1. Chemical structure of a-peptide/b-peptoid peptidomimetics 1 and 2.
Table 1
MIC of plasma (expressed as % of plasma) for all strains used in the present study. MIC of peptidomimetic 1 in MHB, and in MHB supplemented with native
plasma as well as with heat-treated plasma. Nd ¼ not determined; ng ¼ no growth; h.t. ¼ heat-treated. The values are based on two individual experiments
conducted in duplicate.
Target strain MIC of plasma (%) MIC of peptidomimetic 1 (mg $ ml!1)
Added plasma (%)
0 3 6 12.5 25 12.5 h.t.
E. coli %75 2e8 nd nd 0.5e1 0.25e0.5 >64
S. typhimurium 25e50 4e8 nd 1 1e4 ng >512
S. marcescens 12.5 16e128 16 ng ng-2 ng 64
P. aeruginosa 75 128e512 nd nd 16e128 8 >512
V. vulnificus cmcP6 25e75 4e16 nd nd 1e4 0.125e0.25 8e>64
V. vulnificus DSM 10143 25 4e8 nd nd 0.5e2 ng 4e8
V. parahaemolyticus R. 25 4e8 2e4 2e4 ng ng >128
V. parahaemolyticus A. 6 4e8 ng-2 ng-2 ng ng >64
S. aureus 8325-4 75 8e128 nd nd 8e128 2e4 16e>512
S. epidermidis RP62A %75 4e16 nd 0.5e8 nd <0.25 8e64
S. epidermidis 1457 25 4e8 2 1 nd ng >128
L. monocytogenes 6e12.5 8e16 4e8 nd ng ng 8e16
B. cereus %75 2e8 nd nd 0.5e1 0.5e1 4e8
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Table 2
MBC of peptidomimetic 1 in MHB, MHB supplemented with native plasma and with heat-treated plasma, respectively. Nd ¼ not determined; ng ¼ no growth;
h.t. ¼ heat-treated.
Target strain MBC for peptidomimetic 1 (mg $ ml!1)
Added plasma (%)
0 3 6 12.5 25 12.5% h.t.
E. coli 4e16 nd nd 1e8 1e2 >64
S. typhimurium 8e32 nd 1 0.5e4 ng >64
S. marcescens 32e128 16e32 0.125 ng ng 64
P. aeruginosa 512e>512 nd nd 512 >16e>32 >512
V. vulnificus cmcP6 4e16 nd nd 1e2 0.125e0.5 16e>64
V. vulnificus DSM 10143 4e8 nd nd 0.5 ng 4e16
V. parahaemolyticus R. 4e8 2e4 2e4 nd ng >128
V. parahaemolyticus A. 4e8 2 nd ng ng >64
S. aureus 8325-4 32e128 nd nd 8 4e16 16e>64
S. epidermidis RP62A 4e16 nd 1e8 1 >0.25 8e16
S. epidermidis 1457 4e16 4 2 nd ng >128
L. monocytogenes 8e32 8e16 nd &0.125 ng 32
B. cereus 2e16 nd nd 0.5e1 0.5e1 4e8
Table 3
MIC of serum (expressed as % of serum) for all the strains used in the present study. MIC of peptidomimetic 1 in MHB, and in MHB supplemented with native
serum as well as with heat-treated serum. Nd ¼ not determined; ng ¼ no growth; r ¼ resistant to 100% serum; h.t. ¼ heat-treated. The values are based on two
individual experiments conducted in duplicate.
Target strain MIC of serum (%) MIC of peptidomimetic 1 (mg $ ml!1)
Added serum (%)
0 3 6 12.5 25 12.5 h.t.
E. coli r 2e8 nd nd 2e4 4 8e16
S. typhimurium 75 4e8 nd nd 2 2 16e32
S. marcescens 25 16e128 2e32 2e8 ng-0.125 ng >64
P. aeruginosa 75 128e512 nd nd 128e256 64 >512
V. vulnificus cmcP6 50e75 4e16 nd nd 4 2e4 8
V. vulnificus DSM 10143 75 4e8 nd nd 2 2e4 8
V. parahaemolyticus R. 25 4e8 4e>64 4 8e16 <0.125 16e32
V. parahaemolyticus A. 12.5 4e8 2e4 ng-2 8e16 ng 8e16
S. aureus 8325-4 75 8e128 nd nd 32e64 8 256
S. epidermidis RP62A %75 4e16 nd nd 8 2 4e16
S. epidermidis 1457 r 4e8 nd nd 8 2 8
L. monocytogenes r 8e16 nd nd 8e16 8 8e16
B. cereus r 2e8 nd nd 2e4 1e2 4
Table 4
MBC of peptidomimetic 1 in MHB, and in MHB supplemented with native serum and with heat-treated serum, respectively. Nd ¼ not determined; ng¼ no growth;
h.t. ¼ heat-treated.
Target strain MBC for peptidomimetic 1 (mg $ ml!1)
Added serum (%)
0 3 6 12.5 25 12.5% h.t.
E. coli 4e16 nd nd 2e8 4e8 16
S. typhimurium 8e32 nd nd 4e8 2e4 32
S. marcescens 32e128 32 2e8 ng-0.125 ng >64
P. aeruginosa 512e>512 nd nd >256 256 >512
V. vulnificus cmcP6 4e16 nd nd 8 2e8 8e16
V. vulnificus DSM 10143 4e8 nd nd 2e4 2e4 8e16
V. parahaemolyticus R. 4e8 >64 4 8e16 ng-4 16
V. parahaemolyticus A. 4e8 2e4 <0.25e2 8 ng 16
S. aureus 8325-4 32e128 nd nd 64 16e64 512
S. epidermidis RP62A 4e16 nd nd 8 4 8
S. epidermidis 1457 4e16 nd nd 16 2e4 16
L. monocytogenes 8e32 nd nd 16e32 16e32 32
B. cereus 2e16 nd nd 2e8 2 4e8
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(SPS; Sigma Aldrich P2008-5G), an inhibitor of activation of
complement function [24], was dissolved in Tris-buffered sa-
line (1 mg/ml) and added at 50% to plasma and serum for
5 min before MIC assays. Complement protein C3-depleted
and complement-deficient sera were provided by the Depart-
ment for Cancer and Inflammation, University of Southern
Denmark. Complement protein C3-depleted and complement-
deficient sera were stored at !80 "C.
2.6. Time-kill assay of E. coli by peptidomimetic 1 in
presence of human plasma
One colony of E. coli grown overnight on BHI agar at
37 "C was inoculated into MHB and grown overnight at 37 "C
with orbital shaking at 250 rpm. The culture was diluted 106-
fold and grown for 18 h at 37 "C at 200 rpm. Optical density
was adjusted to OD546 ¼ 0.2 in MHB to give an initial inoc-
ulum of 108 CFU/ml. Peptidomimetic 1 was added at con-
centrations of 8, 16, and 32 mg/ml to a final volume of 1 ml.
Killing kinetics was also tested in the presence of 25% plasma.
For this experiment, 13 ml-centrifuge tubes made of poly-
propylene (Almeco 91016) were used. The peptidomimetic-
exposed cultures were incubated at 37 "C at 200 rpm, and
bacterial density was determined by plating of a dilution series
on BHI agar plates after 1, 2, 5, 7 and 24 h of exposure. The
experiment was performed as biological duplicates on two
separate days (each with two technical replicates). Bactericidal
activity of the peptidomimetic alone was compared to the
peptidomimetic in the presence of 25% plasma by Student's t-
test on log-transformed colony counts.
2.7. Visualization of the activity of peptidomimetics by
scanning electron microscopy (SEM)
Many AMPs cause damage to the bacterial cell envelope,
and SEM of peptidomimetic- and plasma-treated E. coli was
used to visualize potential cell envelope damage. E. coli was
grown and diluted (OD546 ¼ 0.2) as described above. Pepti-
domimetic 1 was added at concentrations of 8, 16 or 32 mg/ml.
The influence of 25% plasma (without addition of peptido-
mimetic) on cell morphology was also determined. MilliQ
water was added to control samples. The peptidomimetic-
exposed cultures were incubated at 37 "C at 200 rpm for
2 h; cell density was determined at the start of the exposure
and after 2 h. The total volume after the 2 h treatment was
transferred to Eppendorf tubes and centrifuged at 20,000 $ g
for 15 min in a MiniSpin-Plus Eppendorf 48276. The super-
natant was removed and the cells were fixed for 16 h at 5 "C
by treatment with 3% glutaraldehyde (Sigma Aldrich, G5882)
in 0.5 ml MHB, pH adjusted to 7.3. Next, samples were
washed three times in distilled water followed by staining
with 1% osmium tetroxide (Sigma Aldrich, 75632) overnight
at 5 "C. Dehydration was done by sequential treatment with
ethanol solutions (30%, 50%, 70%, 80%, 90%, 100%) and
acetone solutions (30%, 50%, 100%). Samples were stored
overnight at 5 "C. All washing, staining and dehydration steps
were carried out by applying 0.5 ml of substrate, incubating at
room temperature for 10 min followed by centrifugation at
20,000 $ g for 5 min. After dehydration, the samples were
placed on a silicon disc and further dried in a Leica CPD300
critical point drier. The silicon disc was next attached to an
aluminum stub by means of a double-sided C tape and coated
with 2 nm Pt in a Cressington 208HR High Resolution Sputter
Coater. The experiments were performed in two independent
trials. Cell length was measured from a minimum number of
20 SEM micrographs using NIST Image J on cells lying flat
on the surface. The length was defined as the median line
along the cell length. Cell clustering was avoided by initial
adjustment of the cell number. Also, a hydrophilic substrate
such as a silicon wafer was used in order to ensure that the
bacterial solution was well spread. This preparation favored
the measurement of length of cells lying flat on the analyzed
surface.
3. Results
3.1. MIC and MBC of peptidomimetics in the presence of
plasma and serum
Plasma and serum were initially used at concentrations of
25% and 12.5% based on previous studies with E. coli [16].
Some of the strains in the present study did not grow at these
concentrations, and therefore MICs and MBCs of plasma and
serum were determined. In subsequent experiments, we used
plasma and serum concentrations equivalent to ¼ or ½ of the
MIC of plasma or serum for each strain (Tables 1e4).
Addition of plasma lowered the MIC of peptidomimetic 1
against all strains (Table 1). The presence of 25% plasma
caused a higher potentiation (it lowered the MIC even more)
than addition of 12.5% plasma. The MIC value of peptido-
mimetic 1 was reduced at least 4-fold in the presence of 12.5%
plasma as compared to that in MHB alone for E. coli, S.
typhimurium, P. aeruginosa, V. vulnificus and B. cereus,
whereas no change was observed for S. aureus. For S. mar-
cescens, V. parahaemolyticus, S. epidermidis and L. mono-
cytogenes, plasma could only be tested at concentrations lower
than 12.5%, as mentioned above, but in these cases, a reduc-
tion in the MIC value was observed as well.
A reduction in the MIC value for peptidomimetic 1 in the
presence of 25% plasma, as compared to that found in MHB,
was observed for all strains that grew well at this concentration
(E. coli, P. aeruginosa, V. vulnificus cmcP6, S. aureus and B.
cereus). For strains that did not grow at this concentration, a
reduction in MIC values was observed when determined at
lower plasma concentrations.
In the presence of serum at a concentration of 12.5%, a 2-
fold reduction in the MIC values was typically observed for
Gram-negative strains, except for P. aeruginosa and V. para-
haemolyticus. For these strains as well as for Gram-positive
bacteria, the MIC of peptidomimetic 1 was similar to that
found in MHB alone. When the concentration of serum was
doubled, a reduction in the MIC was observed for P. aerugi-
nosa, V. parahaemolyticus and all Gram-positive bacteria
tested. For V. vulnificus, E. coli and S. typhimurium there was
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no further reduction in the MIC compared to that found in
12.5% serum.
MBC values of peptidomimetic 1 toward most bacteria in
MHB alone were slightly higher than corresponding MIC
values, and relative changes in MBC values observed in the
presence of serum or plasma (Tables 2 and 4) followed trends
analogous to those of MIC values (Tables 1 and 3), inferring
that the apparent synergism between peptidomimetic 1 and
serum/plasma indeed leads to significantly more efficient
killing of a wide range of pathogenic bacteria.
Similar patterns for MIC and MBC were found for pepti-
domimetic 2 (Supplemental Tables S1 and S2).
The effect of plasma on the activity of conventional anti-
biotics and LL-37 was determined for four strains. Human LL-
37 was moderately active against E. coli and P. aeruginosa,
with a MIC of 32e64 mg/ml and 64 mg/ml, respectively; MIC
values against S. aureus were less consistent, ranging from 32
to higher than 512 mg/ml. LL-37 was not potentiated by
plasma, but rather, displayed a 4-fold increase in its MICs
against both E. coli and P. aeruginosa. For S. aureus, MIC
values remained higher than 512 mg/ml (Table 5).
No potentiation of ampicillin in the presence of plasma was
observed (Table 5). The MICs of gentamicin against E. coli
and P. aeruginosa were lowered from 1 to 0.25 mg/ml and
from 1 to 2 to 0.5e1 mg/ml in 25% plasma, respectively, while
no significant effects on the MICs were observed in S. aureus
and L. monocytogenes.
In contrast, the presence of 25% plasma caused a ~10-fold
reduction in the MIC of polymyxin B against E. coli and P.
aeruginosa, while a 4-fold reduction was observed in S. aureus
(Table 5). In L. monocytogenes, the MIC of polymyxin B was
virtually unchanged in the presence of plasma.
3.2. Potentiation of activity of peptidomimetics by
human plasma and serum
MICs and MBCs of peptidomimetic 1 and polymyxin B in
the presence and absence of 25% plasma were assessed using
plates of different materials (Supplemental Table S4). MICs of
both peptidomimetic 1 and polymyxin B were reduced both in
the absence and presence of 25% plasma in the two types of
polypropylene plates. However, in polystyrene plates and glass
vials, the MICs were much higher, probably as a consequence
of substantial binding of these cationic compounds to the
negatively charged surfaces of these materials. Plasma had no
or only a limited effect on the MIC of peptidomimetic 1 in
these systems (polystyrene, glass) most likely as a conse-
quence of partial depletion of active compound in the medium
due to surface adsorption, which inherently becomes relatively
much more pronounced at the very low concentrations tested
in the potentiation experiments.
The human blood used in the experiments was supple-
mented with 4% citrate as an anticoagulant in order to ach-
ieve citrate plasma. As citrate can chelate divalent cations
that stabilize the bacterial cell envelope, it was speculated
that it might be involved in plasma potentiation. Addition of
citrate to serum and to MHB at concentrations of 2e8% and
0.5e4%, respectively, had no effect on the subsequent MIC
values of peptidomimetic 1 (data not shown). Hence, the
potentiation of peptidomimetics was not caused by the citrate
added to plasma. An increase in pH from 7.2 to 8 was
measured when plasma was added to the culture. This change
in pH might affect the charge towards less overall proton-
ation of the peptidomimetic, which would be expected to
lower its affinity toward the cell membrane that would be
equally or slightly more anionic when pH was raised to 8.
However, the MIC of the peptidomimetics in MHB adjusted
to pH 8 did not differ from the MIC in MHB at pH 7.2.
Hence, the pH change caused by the addition of plasma did
not contribute to the increased activity of the peptidomi-
metics, as the bacteria were able to grow equally well under
these conditions.
Plasma and serum were heat-treated to abolish the inherent
activity of the complement system (Tables 1e4). As opposed
to untreated plasma, an increase in the MIC value was seen for
all strains when grown in the presence of 12.5% heat-treated
plasma, indicating lowered sensitivity to peptidomimetics,
possibly due to inactivation of these by interaction with de-
natured plasma components.
Addition of 12.5% heat-treated serum, as compared to
untreated serum, caused no major changes in the MIC values
of peptidomimetic 1 for V. parahaemolyticus ATCC 17802 and
Table 5
MIC and MBC of conventional antibiotics and LL-37 for bacterial pathogens in MHB, and in MHB þ 25% plasma. Nd ¼ not determined; AMP ¼ ampicillin,
GEN ¼ gentamicin, PMB ¼ polymyxin B.
Medium Activity Target strain MIC and MBC (mg $ ml!1)
MHB alone/MHB þ 25% plasma
AMP GEN PMB LL-37
MIC E. coli 4e8/4e8 1/0.25 0.25e0.5/<0.03 32e64/128e256
P. aeruginosa >128/>128 1e2/0.5e1 1/0.06 64/>256
S. aureus 0.125/0.06 0.125e0.25/0.125e0.25 8e16/2e4 32e>512/>512
L. monocytogenes 0.06e0.125/0.25 0.06/0.06e0.125 8e64/32 nd
MBC E. coli 4e8/4e8 1/0.25 0.25e0.5/<0.06 32e64/128e256
P. aeruginosa >128/>128 2e>2/1 2/0.125 64/256
S. aureus 0.125/0.125 0.5/>0.125e1 16e>16/2e>8 >512/>512
L. monocytogenes 0.125e0.25/0.25 0.125/0.06e0.125 16e64/32 nd
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for all the Gram-positive strains except for S. aureus. An
overall increase in the MIC values was found for S. aureus and
all the other strains tested. A similar pattern was observed for
peptidomimetic 2 (Supplemental Tables S1 and S2).
Given these preliminary results, subsequent experiments
were aimed at clarifying the possible involvement of com-
plement. Thus, the effect of sodium polyanethole sulfonate
(SPS) was tested, as it is a specific inhibitor of the complement
system [24]. A considerable increase in the MIC values was
observed when SPS was added during the MIC test. Moreover,
SPS alone abolished the activity of peptidomimetics (data not
shown), and therefore it cannot be used in the present exper-
imental setup to address the possible role of complement. MIC
of peptidomimetics was also determined in the presence of
complement C3-depleted serum and complement factor I- and
H-deficient sera, derived from clinical samples. No change in
the MIC was observed compared to non-depleted or non-
deficient sera (data not shown).
3.3. Time-kill assay of E. coli by peptidomimetic 1 in the
presence of human plasma
Peptidomimetic 1 was bactericidal to E. coli, as cell counts
were significantly decreased after incubation for 2e3 h in a
dose-dependent manner (Fig. 2; panel A). After treatment for
2 h, cell numbers (CFU/ml) were reduced with 1.5, 2.5 and 4
log units when treated with peptidomimetic 1 at 16, 32 and
64 mg/ml, i.e. 2 $ MIC to 8 $ MIC, respectively. The bacteria
grew well in the presence of 25% plasma in MHB, and
interestingly, a more rapid killing of E. coli was seen for
peptidomimetic 1 when 25% plasma was added to MHB
(Fig. 2; panel B). The combination of 8 mg/ml peptidomimetic
and 25% plasma led to a cell reduction of 1.5 log units, which
is similar to using 16 mg/ml peptidomimetic in MHB alone. A
similar effect was observed at 16 mg/ml
peptidomimetic þ 25% plasma compared to 32 mg/ml, as well
as 32 mg/ml þ 25% plasma compared to 64 mg/ml (Fig. 2).
After 24 h (data not shown), we observed a synergistic effect
in the killing of E. coli when 25% plasma and peptidomimetic
were used in combination at concentrations up to 16 mg/ml.
Regrowth was observed in all samples treated with peptido-
mimetics only. For the samples treated with 8 and 16 mg/ml
peptidomimetics, growth was comparable to the controls,
while similar samples supplemented with plasma exerted a
killing effect that was maintained after 24 h. Regrowth could
be explained by partial depletion of the compound due to its
binding to dead bacteria. Small-colony variants were observed
in peptidomimetic-treated samples, both in the presence and
absence of plasma; however, this phenotype was not main-
tained after colonies were re-grown on new agar plates.
3.4. Visualization of cell damage caused by human
plasma
Since many AMPs and peptidomimetics act directly on the
bacterial cell envelope, we speculated that human plasma
might also disrupt the envelope and thereby cause potentiation
via an additive effect. Scanning electron microscopy revealed
no cell membrane damage on E. coli exposed to and grown in
the presence of 25% plasma (Fig. 3, B). In contrast, different
degrees of damage to the cell envelope were evident for
samples treated with increasing concentrations of peptidomi-
metic 1 (Fig. 3, CeF). Damage could be seen as the formation
of blebs (Fig. 3, D), which gave rise to protrusions of the outer
cell membrane (Fig. 3, E) and formation of holes in the apical
part of the cells (Fig. 3, C and F). Addition of 25% plasma to
the samples treated with peptidomimetics at 8 mg/ml and
16 mg/ml, respectively, did not produce further damage (Fig. 3,
D and F) compared to samples treated with 16 mg/ml and
32 mg/ml (Fig. 3, C and E). However, addition of plasma
seemed to affect the average length of the cells. In fact, bac-
teria treated with plasma appeared longer (Supplemental
Fig. S1). This cell elongation was observed after treatment
with plasma, but not with peptidomimetics alone. A few
selected samples were observed in an optical microscope as
well (data not shown). Here, cell aggregation was detected in
Fig. 2. Killing of E. coli by peptidomimetic 1 in MHB (A) and in MHB in the presence of 25% human plasma (B). Counts are averages of biological duplicates and
error bars are standard deviations. 0 mg/ml: solid line; 8 mg/ml: dash dot line; 16 mg/ml: round dot line; 32 mg/ml: dash line; 64 mg/ml: square dot line. The
experiment was performed in the absence and presence of plasma on the same day.
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specimens from samples treated with peptidomimetic plus
plasma, whereas this was not observed for the controls, i.e.
specimens not exposed to either compound or plasma and
specimens exposed solely to plasma.
4. Discussion
Here we demonstrate that the antibacterial activity of two
peptidomimetics against several Gram-negative and Gram-
positive human pathogens is enhanced by the presence of
human plasma and, to some extent, by the presence of human
serum. From a clinical perspective, this is a promising finding,
since it is likely that lower concentrations of peptidomimetics
may be used in clinical settings than usually expected based on
testing in laboratory growth media.
For the peptidomimetics investigated in the present study,
the concentration that causes 10% hemolysis (HC10) was
previously found to be above 500 mg/ml [20], indicating low
general cellular toxicity. In addition, peptidomimetic 1 was
previously shown to exert acceptable cell selectivity between
S. epidermidis and HeLa cells (i.e. the ratio between IC50 and
MIC was above 200) [20] despite the fact that this cell line is
more susceptible to these antibacterial peptidomimetics than
other more relevant cell lines (e.g. HepG2, NIH 3T3 and
HUVEC) [19]. Moreover, as shown by Jahnsen et al. [19], this
type of peptidomimetics may be further optimized toward
even lower cytotoxicity by partial hArg/Lys substitution.
Thus, the finding that human plasma potentiates the antibac-
terial effect of compounds 1 and 2 further supports their po-
tential use in vivo, as cytotoxic side effects are highly
concentration-dependent and therefore will decrease signifi-
cantly when the concentration needed for bacterial killing is
lowered 2- to 16-fold.
The potentiation of antibacterial compounds by plasma
could be caused by endogenous blood components such as
complement proteins. Hein-Kristensen et al. [16] suggested
that complement factors might be responsible for the plasma-
enhanced activity of membrane-active AMPs and peptidomi-
metics against E. coli due to the fact that heat inactivation of
complement [25] abolished this synergism, a finding corrob-
orated by the present study in which we extended its validity
to several bacterial species.
Fig. 3. Scanning electron microscopy (SEM) images of E. coli. (A) untreated; (B) untreated þ 25% plasma; upon treatment with peptidomimetic 1: (C) 16 mg/ml,
(D) 8 mg/ml þ 25% plasma, (E) 32 mg/ml, (F) 16 mg/ml þ 25% plasma.
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Activation of complement results in formation of the
membrane attack complex (MAC) that generates pores in
Gram-negative bacterial cell membranes. The role of AMPs
as immune potentiators and signaling molecules is well-
known, and it has recently been found that they share a
number of features with complement [26]. Thus, given the
membrane-perturbing effect of AMPs and antibacterial
peptidomimetics, a synergistic effect between peptidomi-
metics and complement system appeared likely. Neverthe-
less, we observed no visible damage to the envelope when E.
coli was exposed to plasma when examined by SEM. On the
other hand, we found a dramatic increase in MIC in the
presence of heat-inactivated plasma, supporting the
assumption that one or more heat-sensitive protein(s)
involved in the mechanism of plasma potentiation had suf-
fered from denaturation.
Selected factors of the complement cascade such as factor
H, factor I, and complement C3 did not seem, individually, to
be the cause of potentiation based on testing of C3-depleted,
factor H- and factor I-deficient sera. However, since MIC
values were affected significantly more by plasma than by
serum, and since both contain relevant complement proteins,
future experiments should preferably involve purified com-
plement factors and coagulation proteins.
Besides complement proteins, other factors, such as pro-
teins of the coagulation cascade, could contribute to the effect
of potentiation. This would explain why plasma gives rise to
higher potentiation of peptidomimetics than serum. Unlike
serum, the commercial plasma (P9523 www.sigmaaldrich.
com) contains active clotting factors, which may respond to
the presence of microorganisms. Activation of complement
proteins and the coagulation cascade are connected [27], and
complement is known to inhibit anticoagulation factors,
thereby enhancing the coagulation process. Other studies [28]
reported that specific coagulation factors in plasma promote
the release of antimicrobial compounds directed toward the
negatively charged surfaces of bacterial pathogens. From all
these interconnected processes, it is inferred that higher
potentiation of peptidomimetics by plasma could indeed arise
from favorable interactions requiring the presence of both
complement and clotting factors, given that the latter is absent
in serum. However, it is also evident that only whole-blood
models would mirror the cross-talk between the different
systems acting in vivo [27].
Plasma enhanced the antibacterial effect of polymyxin B,
but not that of gentamicin or ampicillin (Table 5). Given the
membrane-perturbing effect of the peptidomimetics, as
revealed by SEM and leakage of intracellular compounds [29],
we conclude that the potentiation by plasma is related to the
finding that the bacterial membrane appears to be the major
target of these peptidomimetics. Other studies have reported
that complement proteins can act in synergy with antibacterial
compounds such as antibiotics [30] and AMPs [12], and for
instance, the activity of polymyxin B is potentiated by serum
[31]. Interestingly, it was found that terminal complement
components are involved in the enhancement of the antibac-
terial effect of polymyxin B. In contrast, no synergistic effects
between serum and b-lactams or aminoglycoside antibiotics
were reported [32].
The activity of a-helical human cathelicidin LL-37 was
decreased in the presence of plasma. Indeed, Wang et al. found
that human plasma inhibits the antibacterial activity of LL-37,
and it was proposed that LL-37 binds to a 30-kDa plasma
protein [33]. LL-37 is a cationic natural human host defense
peptide, and reducing its activity by binding to blood com-
ponents might have evolved as a mechanism to balance its
otherwise cytotoxic effects in vivo [34], whereas synthetic
highly cationic non-helical and/or non-amphipathic com-
pounds may not be bound by blood components. Also, LL-37
can be inactivated after binding to the Lpp receptor in E. coli
[35]. This interpretation may explain the high MICs found for
this AMP when determined in MHB.
The bacterial pathogens differed in their sensitivity to blood
matrices. This could be attributed to differences in their pro-
pensity to interact with the bacteriolytic or bactericidal com-
plement factors [36], since some pathogens are able to survive
in serum or plasma at certain concentrations due to their
natural virulence factors or resistance mechanisms. Staphylo-
cocci [37] and Pseudomonas spp. [38] are more resistant to
blood than other pathogens, which is in accordance with our
results, as Pseudomonas and Staphylococcus were among the
strains that grew well in 25% plasma. In contrast, Vibrio
parahaemolyticus is more sensitive to serum than V. vulnificus
[39], as also seen in the present study for both serum and
plasma.
However, since the killing efficiency of peptidomimetics
was enhanced in the presence of plasma, it is suggested that:
(i) the inherent resistance mechanisms may be impaired by the
peptidomimetics, and/or (ii) potentiation of the peptidomi-
metics involves plasma components that alone do not exert a
killing effect.
Electron microscopy (EM) is a valuable tool for visualizing
the effects of antimicrobial peptides on the bacterial cell en-
velope [40], and here we demonstrate that the membrane-
perturbing effects of a-peptide/b-peptoid peptidomimetics
can also be documented by scanning EM (Fig. 3, CeF). Our
results are consistent with previous studies where AMPs and
peptoid mimics caused formation of blebs, pore formation and
cell lysis [41,42]. In addition, we detected stronger occurrence
of damage to the apical part of the cell, a feature that was
noted earlier by Klainer and Perkins [43]. It is remarkable that
cells treated with peptidomimetics in the presence of plasma
often appeared longer than those treated in the absence of
plasma. This elongation may well be a symptom of delayed or
inhibited cell division, as noticed by Klainer and Perkins [43]
when E. coli was treated with a sub-MIC concentration of
penicillin. Chileveru et al. [44] also reported cell elongation
after treatment of Gram-negative bacteria with human
defensin-5, which was hypothesized to involve inhibition of
cell division.
Overall, the present results show that the activity of
membrane-active peptidomimetics against a range of Gram-
positive and Gram-negative pathogenic bacteria is potenti-
ated by the presence of human plasma. The potentiation effect
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of plasma is dependent on the mode of action of the anti-
bacterial compound used (as seen for the conventional anti-
biotics tested), since only compounds acting on the cell
membrane or envelope appear to be potentiated by plasma. We
hypothesize, but cannot conclude, that complement factors are
involved in this potentiation. Also, we hypothesize that
coagulation proteins may act in synergy with complement and
increase the bactericidal effect of peptidomimetics, or vice-
versa.
If future studies show that findings from such experiments
may indeed be translated into animal proof-of-concept studies,
a long-term perspective is that decreased dosing of certain
classes of antibiotics might be applied in the treatment of in-
fectious diseases.
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Supplemental Table S1: MIC of peptidomimetic 2 in MHB, MHB supplemented with native serum or plasma as well as with heat-treated serum or 




MIC for peptidomimetic 2 (µg  ml–1) 
MHB 
Control 
Added serum (%) Added plasma (%) 12.5% heat-treated 
3 6 12.5 25 3 6 12.5 25 serum plasma 
E. coli 4-8 nd nd 4-8 4-8 nd nd 1-2 0.5-1 16-32 16->64 
S. typhimurium 8-16 nd nd 8-16 8-16 nd 4 2-8 ng 64-128 16->64 
S. marcescens 16-512 4-64 1-4 ng-0.125 ng 16-32 ng ng-4 ng >64 >512 
P. aeruginosa 128-512 nd nd 128-256 128-256 nd nd 16-128 16-32 >512 >512 
V. vulnificus cmcP6 4-16 nd nd 4-8 4 nd nd 2-4 0.5-1 4-16 8->64 
V vulnificus DSM 10143 4-16 nd nd 2-4 4-8 nd nd 1-4 ng 16 16 
V. parahaemolyticus R. 4-8 4 8-16 8-16 ng-<0.125 4  2-4  ng ng 32-64 >128 
V. parahaemolyticus A. 4-8 1-4 ng ng  ng ng-2 ng ng ng 32 >64 
S. aureus 8-64 nd nd 8->32 4 nd nd 4-8 2 64-128 >64->512 
S. epidermidis RP62A 4-8 nd nd 4 2 nd  0.25-2   0.5 ng-<0.25 8-16 16->64 
S. epidermidis 1457 2-8 nd nd 4 2 0.5-1 0.5-1 nd ng 8 >128 
L. monocytogenes 2-8 nd nd 8 8 2-4 nd ng ng 8-16 8-16 
B. cereus 2-8 nd nd 4-8 2-4 nd nd 1-2 1 8-16 8 
  
Supplemental Table S2: MBC of peptidomimetic 2 in MHB, MHB supplemented with native serum or plasma as well as with heat-treated 




MBC for peptidomimetic 2 (µg ×  ml–1) 
MHB 
Control 
Added serum (%) Added plasma (%) 12.5% heat-treated 
   3     6     12.5      25       3        6         12.5         25        serum  plasma 
E. coli 4-16 nd nd 4-16 4-8 nd nd 2-16 0.5-8 32 32->64 
S. typhimurium 8-16 nd nd 4-32 16 nd 4-8 0.5-8 0.25-ng 64 >64 
S. marcescens 16-128 64 4 ng-0.125 ng 16-32 ng ng ng >64 64 
P. aeruginosa 128->512 nd nd >256 >512 nd nd 512 >32-64 >512 >512 
V. vulnificus cmcP6 8-32 nd nd 8-16 4-8 nd nd 4 0.5-2 8-16 16->64 
V vulnificus DSM 10143 4-16 nd nd 2-4 8 nd nd 1 ng-0.125 16 16 
V. parahaemolyticus R. 8-16 4 8-16 16 ng-4 4 2-4 nd ng 32 >64 
V. parahaemolyticus A. 4-8 4 ng ng  ng  2 ng ng     ng 32-64       >64 
S. aureus 8-128 nd nd 16->32 8-16 nd nd 16 4-8 128 >64->512 
S. epidermidis RP62A 4-8 nd nd 4 2-4 nd   0.5-4 1 >0.25 16 >64 
S. epidermidis 1457 4-8 nd nd 4-8 2-4 1 1 nd nd 8 >128 
L. monocytogenes 2-8 nd nd 16 8-16 4 nd nd nd 32 16 




Supplemental Table S3: Bacterial strains used in the present study and relative reference. 
 
Strain name Reference 
Escherichia coli ATCC 25922 - 
Salmonella typhimurium L354 Wray C. 1978. Experimental Salmonella Typhimurium infection in calves. Res Vet Sci 
25(2):139-143. 
Serratia marcescens Hejazi A, Falkiner FR. 1997. Serratia marcescens J Med Microbiol 46(11):903-912. 
Vibrio vulnificus DSM 10143 Reichelt JL, Baumann P, Baumann L. 1976. Study of genetic relationships among 
marine species of the genera Beneckea and Photobacterium by means of in vitro 
DNA/DNA hybridization. Arch Microbiol 110(1):101-120.  
Vibrio vulnificus cmcP6 Kim YR, Lee SE, Kim CM, Kim SY, Shin EK, Shin DH, Chung SS, Choy HE, 
Progulske-Fox A, Hillman JD, Handfield M, Rhee JH. 2003. Characterization and 
pathogenic significance of Vibrio vulnificus antigens preferentially expressed in 
septicemic patients. Infect Immun 71(10):5461-5471. 
Vibrio parahaemolyticus ATCC 17802 - 
Vibrio parahaemolyticus RimD D2210633 Nasu H. 2000. A filamentous phage associated with recent pandemic Vibrio 
parahaemolyticus O3!: K6 strains. J Clin Microbiol 38(6):2156-2161. 
Pseudomonas aeruginosa PAO1 Holloway B. 1955. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 
13(3):572-581. 
Listeria monocytogenes EGDe BUG 1600 Glaser P, Frangeul L, Buchrieser C, Rusniok C, Amend A, Baquero F, et al., Cossart P. 
2001. Comparative genomics of Listeria species. Science 294(5543):849-52.  
Bacillus cereus ATCC 11778 - 
Staphylococcus aureus 8325 Novick R. 1967. Properties of a cryptic high-frequency transducing phage in 
Staphylococcus aureus. Virology 33(1):155-166.  
Staphylococcus epidermidis RP62A Christensen GD, Simpson WA, Bisno AL, Beachey EH. 1982. Adherence of slime-
producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun 
37(1):318-326.   
Staphylococcus epidermidis 1457 Rupp ME, Ulphani JS, Fey PD, Mack D. 1999. Characterization of Staphylococcus 
epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of 




Supplemental Table S4: MIC and MBC of peptidomimetic 1 (1) and polymyxin B (PMB) against E. coli in absence and presence of 25% 
plasma. MIC was assessed in the listed materials. Polypropylenea: plates sterilized by autoclave; polypropyleneb: UV-sterilized plates. The 





1 1 + 25% plasma PMB PMB + 25% plasma 
Polypropylenea  4-8 / 4-16 0.5-1 / 2-4 0.5 / 0.5 0.007-0.03 / 0.007-0.125 
Polypropyleneb 2-4 / 4-8 0.125-0.25 / 0.5-1 0.5-1 / 0.5-1 0.007-0.015 / 0.007-0.06 
Polystyrene 16 / 16 4-8 / 16 2-4 / 2-4 >0.5-0.5 / >0.5-0.5   







Supplemental Figure S1: Number of cells with relative length for MHB-treated sample (blue bars) and sample treated with MHB + 25% 
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Antimicrobial peptides (AMPs) have for long been considered as potential new antimicrobials since resistance appears not to evolve
readily in nature. However, adaptive laboratory evolution experiments (ALE) have demonstrated that bacteria may develop
resistance also to AMPs. We, as others, hypothesize that the risk of resistance development decreases when two or more
compounds are combined as compared to single-drug treatment. The purpose of the study was to investigate resistance
development in E. coli ATCC 25922 when exposed to a combination of three compounds and to each of the compounds separately
(peptidomimetic H‐[Lys‐βNSpe‐hArg‐βNSpe]3‐NH2 and the AMPs novicidin and P9‐4).
Surprisingly, none of the lineages exposed to P9‐4 adapted to a 32‐fold higher MIC, while all lineages exposed to H‐[Lys‐βNSpe‐
hArg‐βNSpe]3‐NH2 and three out of four lineages exposed to novicidin adapted to a 32‐fold higher MIC than the wild type MIC, after
passaging through approx. 350 generations. Only one out of four lineages exposed to the combination reached a 32-fold higher MIC
of 256 μg/ml. The whole genomes of adapted lineages and individual clones were sequenced and analyzed, and an average of 6
single-nucleotide variants causing amino acid change were detected in the peptide-adapted lineages, while an average of 5 single-
nucleotide variants were found in the control lineages. The most common variants in adapted lineages (and derived clones) were
deletions in the gene encoding the enzyme CDP-glycerophosphotransferase, present in six out of eight adapted lineages and in
eleven clones. The zeta potential of adapted lineages was less negative than that of the wild type, suggesting that a contributing
factor to the gained resistance involve modification of the surface charge.
The results indicate that a common evolutionary trajectory has led to development of resistance both to the individual compounds
and to a combination of all three compounds. The short antimicrobial peptide P9-4, giving rise to a slow resistance development
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Antimicrobial peptides (AMPs) have for long been considered as potential new antimicrobials since 24 
resistance appears not to evolve readily in nature. However, adaptive laboratory evolution 25 
experiments (ALE) have demonstrated that bacteria may develop resistance also to AMPs. We, as 26 
others, hypothesize that the risk of resistance development decreases when two or more compounds 27 
are combined as compared to single-drug treatment. The purpose of the study was to investigate 28 
resistance development in E. coli ATCC 25922 when exposed to a combination of three compounds 29 
and to each of the compounds separately (peptidomimetic H-[Lys-βNSpe-hArg-βNSpe]3-NH2 and 30 
the AMPs novicidin and P9-4). 31 
 32 
Surprisingly, none of the lineages exposed to P9-4 adapted to a 32-fold higher MIC, while all 33 
lineages exposed to H-[Lys-βNSpe-hArg-βNSpe]3-NH2 and three out of four lineages exposed to 34 
novicidin adapted to a 32-fold higher MIC than the wild type MIC, after passaging through approx. 35 
350 generations. Only one out of four lineages exposed to the combination reached a 32-fold higher 36 
MIC of 256 µg/ml. The whole genomes of adapted lineages and individual clones were sequenced 37 
and analyzed, and an average of 6 single-nucleotide variants causing amino acid change were 38 
detected in the peptide-adapted lineages, while an average of 5 single-nucleotide variants were 39 
found in the control lineages. The most common variants in adapted lineages (and derived clones) 40 
were deletions in the gene encoding the enzyme CDP-glycerophosphotransferase, present in six out 41 
of eight adapted lineages and in eleven clones. The zeta potential of adapted lineages was less 42 
negative than that of the wild type, suggesting that a contributing factor to the gained resistance 43 








The results indicate that a common evolutionary trajectory has led to development of resistance 46 
both to the individual compounds and to a combination of all three compounds. The short 47 
antimicrobial peptide P9-4, giving rise to a slow resistance development rate, may be considered a 48 
promising candidate for further optimization and future application in clinical settings. 49 
1 Introduction 50 
Development of bacterial resistance to conventional antibiotics is a global concern (Fair and Tor, 51 
2014), and it has recently been highlighted as one of the major challenges facing mankind (WHO 52 
Report, 2014). Consequently, there is an urgent need for exploration of new antibacterial 53 
compounds as well as more effective regimens for use of both existing and novel antibiotics. 54 
Antimicrobial peptides (AMPs) have been suggested as such novel antibacterial agents (Hancock 55 
and Sahl, 2006), despite common limitations such as cytotoxic side effects or sensitivity to 56 
proteolytic degradation (Chongsiriwatana et al., 2008). Peptidomimetics mimicking the biological 57 
activity of AMPs have been investigated, and some subclasses have proved to overcome these 58 
shortcomings of AMPs (Jahnsen et al., 2012).  59 
 60 
AMPs have evolved to constitute an essential part of the antimicrobial defense system of most 61 
living organisms, and AMP resistance in natural innate immune system settings has not been 62 
reported (Malmsten, 2014). AMPs typically act as detergent-like compounds causing either pore 63 
formation or disruption of the cell envelope (Brogden, 2005), and it has been stated that resistance 64 
to AMPs will not develop as readily as it develops toward conventional antibiotics (Marr et al., 65 
2006). Also, it is believed that development of resistance to AMPs is impeded by their rapid 66 
bactericidal activity (Fox, 2013).  67 
 68 
However, since AMPs target conserved structures in the bacterial cell envelope, bacterial evolution 69 
have resulted in systems that circumvent their action, i.e. a parallel evolutionary race exists between 70 
pathogens and their hosts (Peschel and Sahl, 2006). Several authors (Devine and Hancock, 2002) 71 
(Nizet, 2006; Maria-Neto et al., 2015) have described a series of bacterial mechanisms of intrinsic 72 
resistance against AMPs. Also, for some compounds, resistant mutants are selected for when 73 
bacteria are exposed to sub-lethal concentrations (Cassone and Otvos, 2010) or when allowed to 74 
adapt over longer periods to AMPs (Perron et al., 2006) or peptidomimetics (Hein-Kristensen et al., 75 
2013). Mutations leading to cell membrane modifications are likely to confer resistance to AMPs; 76 
however, the exact mechanisms of resistance to AMPs are not fully understood (Maria-Neto et al., 77 
2015). Whole-genome sequencing of the end-point resistant lineages selected for may provide a 78 
more detailed insight into the molecular mechanisms underlying resistance (Köser et al., 2014). The 79 
pattern of mutation events may thus clarify whether resistance development involves a particular 80 
evolutionary trajectory (de Visser and Krug, 2014). Also, the understanding of resistance 81 
mechanisms is essential for discovery of potential targets useful for treatment of drug-resistant 82 
bacteria (Punina et al., 2015) (Cole and Nizet, 2016). 83 
 84 
Most studies on AMPs and peptidomimetics have focused on their spectrum of activity, cost of 85 
production, the dose needed, and their efficacy in clinical trials (Brogden and Brogden, 2011). 86 
However, assessing the potential for resistance development is an important part of the evaluation 87 
of novel antibacterial compounds. All antimicrobials must be used in ways that optimize their effect 88 
at the lowest possible concentration and reduce the risk of resistance development. One strategy is 89 
to apply combination therapy that may provide an enhanced antibacterial effect in vitro via 90 
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synergistic effects (Zhuang et al., 2015; Galani et al., 2014). Thus, by combining drugs, the dose of 91 
each compound may be reduced whereby potential toxicity in vivo may be abolished (Pirrone et al., 92 
2011). Further, a combination of several antibiotics may impose additional evolutionary restraints 93 
on the bacterial population (Lindsey et al., 2013) thereby suppressing the viability of mutants that 94 
otherwise might overcome the mode of action of the individual drugs. 95 
 96 
Combination treatment has been successfully applied for HIV treatment (Lennox et al., 2009), 97 
malaria (Nyunt and Plowe, 2007), tuberculosis (Ortona et al., 1998), and it is used for treatment of 98 
severe infections with carbapenemase-producing Enterobacteriaceae (Qureshi et al., 2012). Several 99 
in vitro studies have shown the potential of combination treatment based on AMPs 100 
(Chongsiriwatana et al., 2011; Yu et al., 2016) and AMPs together with conventional antibiotics 101 
(Hindler et al., 2015). In fact, AMPs have the advantage of acting in synergy in the natural host 102 
environment (Cassone and Otovs, 2010). 103 
 104 
AMPs act mainly by binding to different macromolecules in the bacterial cell membrane, and 105 
therefore typically have multiple low-affinity targets in contrast to conventional antibiotics. When 106 
the bacterial cell is targeted in a multi-mode way, resistance development is slowed down due to 107 
increased cost of fitness for the induced mutations. Hence, simultaneous alteration of several targets 108 
would appear less probable than it would be for single-target molecules (Sallum and Chen, 2008). 109 
In a combination approach, such multiple mutations would be of less probability due to an even 110 
higher number of potential target molecules.  111 
 112 
The purpose of the present study was to assess the risk of resistance development to two AMPs and 113 
a peptidomimetic. We also addressed the hypothesis that resistance to a cocktail of compounds 114 
would develop slower than against each compound alone.  115 
 116 
2 Material and methods 117 
 118 
2.1 Bacterial strain and culture conditions.  119 
 120 
Escherichia coli ATCC 25922 was grown in cation-adjusted Müller Hinton II broth (MHB) (Becton 121 
Dickinson 212322) adjusted to pH 7.4 and supplemented with 1.5% agar (Oxoid, CM0471) for 122 
culturing on solid medium. Stock cultures of this strain and resulting adapted lineages were stored 123 
at –80 ⁰C in 25% glycerol. 124 
 125 
2.2 Synthesis of peptidomimetics and AMPs.  126 
 127 
The potential development of resistance was tested by using three compounds: the peptidomimetic 128 
H-[Lys-βNSpe-hArg-βNSpe]3-NH2 that displays an unnatural backbone with some degree of a non-129 
helical secondary structure (Jahnsen et al., 2014; Figure 1), the AMP novicidin 130 
(KNLRRIIRKGIHIIKKYF-NH2), a typical α-helical arginine/lysine-rich peptide (Nielsen and 131 
Otzen, 2010), and the AMP P9-4 (KWRRWIRWL) that most likely does not form a secondary 132 
structure due to its short length (Qi et al., 2010). H-[Lys-βNSpe-hArg-βNSpe]3-NH2, novicidin and 133 
P9-4 were used in the adaptation and were abbreviated as “1”, “2”, “3”, respectively. Compounds 134 
used for assessment of cross resistance were the following: 5 (Ac-[hArg-βNSce-Lys-βNSpe]3-NH2), 135 
6 (Ac-[Lys-βNphe]8-NH2), 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2) as shown in 136 
Figure 1. 137 
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All the compounds were prepared by solid-phase synthesis as previously described (Bonke et al., 138 
2008; Olsen et al., 2010). The resulting lyophilized peptidomimetics and AMPs were dissolved in 139 
10 mg/ml sterile MilliQ water and stored at –20 ⁰C.  140 
 141 
2.3. Determination of Minimum Inhibitory Concentration (MIC).  142 
 143 
MIC of each compound alone, combinations of each of two compounds and of all three was 144 
determined. When testing mixtures of two compounds, each was included at 50% and when testing 145 
the combination of three, each was included at 33% of the total (Table 1). MIC was determined as 146 
described in (Citterio et al., 2016) in accordance with the CLSI guidelines (2012). Microdilution 147 
series of the compounds were prepared in UV-sterilized 96-well polypropylene plates (Thermo 148 
Scientific Nunc, 267334) with sterile polystyrene lids (Sigma Aldrich, CLS3930-100EA). Stock 149 
solutions of peptidomimetics and AMPs were prepared in MilliQ water. Fifty µl of compound 150 
solution and 50 µl of MHB were dispensed into the first well of each row, followed by two-fold 151 
dilutions giving a final concentration range of 128-0.25 µg/ml. Overnight culture of the strain was 152 
diluted in sterile 0.9% NaCl to OD546 0.2 (accepted range: 0.195-0.210) corresponding to 153 
approximately 1 × 108 CFU/ml. This suspension was further diluted 1:100 in MHB and 50 µl of this 154 
culture were inoculated into microtiter plates to reach a final concentration of 5 × 105 CFU/ml in a 155 
final volume of 100 µl. Plates were incubated for 20 h at 37 °C. Growth was determined visually 156 
either as turbidity or as formation of a pellet. MIC was the lowest concentration of peptidomimetics 157 
or AMPs where no growth was observed. All MIC assays were performed as two independent 158 
replicates. 159 
 160 
2.4 Adaptive Laboratory Evolution (ALE).  161 
 162 
Adaptive laboratory evolution of E. coli was carried out as previously described (Perron et al., 163 
2006) in presence of each compound alone and in a combination of all three compounds. An 164 
overnight culture of the strain was grown on MHB agar at 37 °C. A single colony was inoculated in 165 
liquid MHB and grown overnight at 37 °C at 250 rpm on orbital shaker. The initial culture was 166 
adjusted to OD546 = 0.2 and 10 µl were inoculated into 990 µl MHB giving 1 ml of final volume. 167 
Cultures were grown in Sterilin tubes (VWR, 212-7400) at 37 °C at 250 rpm. Throughout the 168 
experiment serial transfers of 10 µl of bacterial culture to fresh medium were performed when 169 
growth was visible as turbidity. After five transfers in un-supplemented medium, four different 170 
peptide treatments were tested: H-[Lys-βNSpe-hArg-βNSpe]3-NH2, novicidin, P9-4, and the 171 
combination of the three (mixed 1:1:1). Four replicates (lineages) were prepared for each treatment, 172 
with the addition of four un-supplemented cultures (i.e. non-exposed lineages), giving a total of 20 173 
parallel lineages. As a simplification, the four lineages adapted to H-[Lys-βNSpe-hArg-βNSpe]3-174 
NH2 (1) were referred to as “1a”, 1b”, “1c” and “1d” through the course of the manuscript. Lineages 175 
adapted to novicidin (2) were referred to as “2a”, 2b”, “2c” and “2d”, lineages adapted to P9-4 (3) 176 
were indicated as “3a”, 3b”, “3c” and “3d”, and lineages adapted to the combination of three were 177 
designated “4a”, 4b”, “4c” and “4d”. Among non-exposed lineages, we selected lineages “0a” and 178 
“0b”, that were transferred until the adaptation experiment was ended, and lineages “0c” and “0d” 179 
that were transferred until the first adaptation to 32-fold of the initial MIC was completed. 180 
Adaptation started from 1/16 of the wild type MIC (i.e. 0.25 µg/ml for 1a, 1b, 1c and 1d; 0.5 µg/ml 181 
for lineages 2a, 2b, 2c and 2d and 3a, 3b, 3c and 3d; and 0.5 µg/ml for 4a, 4b, 4c and 4d). Five 182 
transfers at constant concentration were performed. Then the concentration was doubled and the 183 
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experiment continued until a level of 32-fold higher MIC than wild type MIC was reached for most 184 
of the lineages. After each adaptation step, frozen stocks of the adapted culture were prepared. 185 
 186 
Purity of the lineages was checked at each transfer by streaking on MHB agar plate. The total 187 
number of passages in presence of compound was 50, equivalent to approximately 350 generations. 188 
Re-inoculations were performed twice a day during the sub-MIC treatment and then reduced to 189 
once per day when growth became slower, as the concentration of compound was increased. In case 190 
no growth was observed the next day, the tube was left for another day. If growth still did not occur, 191 
the re-inoculation step was repeated in the same concentration as used in the previously grown 192 
culture. If still no growth was seen, concentration was halved. End of a lineage was considered to be 193 
reached when no growth was observed upon five consecutive re-inoculations. 194 
 195 
To determine stability of the resistance, MIC was determined for each adapted lineage. Overnight 196 
cultures for this assay were prepared in presence of compound at the concentration each lineage was 197 
adapted to. For lineages that did not grow overnight under these conditions the compound 198 
concentration was decreased. Furthermore, the adapted lineages were re-inoculated five times in un-199 
supplemented medium, and MIC was determined for all of them. To assess homogeneity of the 200 
lineage community, the lineages were streaked on agar plates, and then five individual clones 201 
(colonies) were isolated after overnight growth on solid medium. Clones were enumerated from 1 to 202 
5. As an example, clone 1 isolated from the novicidin-adapted lineage “a” was indicated as 2a-1. 203 
MIC was also determined for all the clones.  204 
 205 
2.5 Whole-genome sequencing and variant calling. 206 
 207 
Lineages for whole-genome sequencing were chosen based on the results from the MIC assay 208 
performed on the adapted cultures and the respective clones. Two replicates of two control lineages 209 
and four adapted lineages were selected, giving a number of 12 genomes. Also, two out of five 210 
individual clones were considered for each replicate, giving a number of 24 genomes. Of the control 211 
lineages, half was derived from un-supplemented cultures that were transferred until the first 212 
adaptation to a 32-fold higher MIC had occurred; the other half was derived from un-supplemented 213 
cultures that were serially transferred until the experiment was completed. The wild type ancestral 214 
strain (E. coli ATCC 25922) was sequenced as well. Hence, a total number of 37 lineages and 215 
clones were whole-genome sequenced.  216 
 217 
An overnight culture of E. coli (1.5 ml) was grown to stationary phase and genomic DNA was 218 
extracted with the NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany). Quality of extracted 219 
DNA was assessed by 1% agarose gel electrophoresis and absorbance measurement at DeNovix 220 
DS-11 Spectrophotometer. Quantification was done by Qubit 2.0 Fluorometer (Invitrogen, United 221 
Kingdom). Preparation of genomic DNA libraries and sequencing was performed at the Novo 222 
Nordisk Foundation Center for Biosustainability (Hørsholm, Denmark). Libraries were prepared 223 
with TruSeq Nano HT (Illumina, San Diego, USA) and fragmented to an average size of 350-400 224 
bp with CovarisE220. Average library size after adapter ligation was 500-550 bp, determined by 225 
Fragment Analyzer and Standard Sensitivity NGS kit. Concentrations of the final libraries were 226 
measured by Qubit, dsDNA broad range assay. Libraries were used for paired-end sequencing of 227 
genomes using the Illumina sequencing technology on a NextSeq v2 Mid Output 300 cycles 228 
(2x150). The obtained sequence reads of the wild type strain were de novo assembled in CLC 229 
Genomics Workbench, version 8 (CLC Bio, Aarhus, Denmark) resulting into 156 contigs, 230 
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comprising a total number of 5122028 bases, with a genome coverage of 89×. The assembled 231 
genome has been deposited at GenBank under the BioProject PRJNA309047. All other 36 genome 232 
sequences were submitted to the Sequence Read Archive (SRA) database under the accession 233 
number SRP075796. All the sequenced genomes from adapted and control lineages were mapped 234 
with the 156 contigs as a reference. Average genome coverage was 104×. The 156 contigs were 235 
annotated by Rapid Annotation using Subsystem Technology (Aziz et al., 2008). Variants were 236 
called by fixed ploidy variant detection in CLC Genomics Workbench, in order to identify point 237 
mutations such as Single Nucleotide Polymorphisms (SNPs) and deletion-insertion-polymorphism 238 
(DIPs). Variants with a frequency above 60% were considered for further analysis. Functional 239 
consequences were predicted by searching for amino acid changes, and then filtering non-240 
synonymous mutations.  241 
The analysis was repeated by assembling the wild type contigs to the previously annotated genome 242 
of E. coli ATCC 25922, available at GenBank with the accession number CP009072 (Minogue et 243 
al., 2014). Wild type variants, in comparison to this genome, were detected and shown in 244 
Supplementary Table 2. All the adapted lineages were then mapped to the annotated genome. 245 
Variants were detected and filtered against the known ones, already found in the wild type.  246 
 247 
2.6 Measurement of Zeta potential.  248 
 249 
The wild type strain, an adapted lineage (3c) and a clone (1a-1) were grown overnight in 2 ml liquid 250 
MHB at 37 °C at 250 rpm on an orbital shaker. Cultures were grown both in presence and absence 251 
of compound. Cells were harvested in Eppendorf 5810R centrifuge at 2250 × g for 20 min. Cell 252 
pellets were washed five times in 0.5 mM potassium phosphate buffer solution (pH 7.4), in 253 
Eppendorf 5417R centrifuge at 3000 × g for 5 min, as described in Halder et al., (2015). OD600 was 254 
adjusted to 0.2 (corresponding to approximately 1 × 108 CFU/ml). Zeta potential was measured 255 
with a Zetasizer Nano ZS90 device (Malvern, UK). The given values resulted from the average of 256 
three technical replicates, each of them consisting of 20 measurements. The experiment was 257 
repeated a second time on a separate day. Statistical significance was assessed by One-way analysis 258 
of variance (ANOVA) with statistical F test.  259 
 260 
3 Results  261 
 262 
3.1 Adaptive laboratory evolution.  263 
All four lineages exposed to H-[Lys-βNSpe-hArg-βNSpe]3-NH2 (1a to 1d) and three out of four 264 
lineages exposed to novicidin (2b 2c, 2d) were adapted to a 32-fold higher MIC (128 and 256 265 
µg/ml, respectively) after passaging through approximately 350 generations (Figure 2). 266 
Unexpectedly, none of the lineages exposed to P9-4 (3a to 3d) adapted to a 32-fold higher MIC, but 267 
only one of four lineages (3c) tolerated a 16-fold higher MIC of 128 µg/ml), whereas the other three 268 
i.e. 3a, 3b, 3d remained at 8-, 4- and 4-fold higher MIC (64 and 32 µg/ml, respectively) as shown in 269 
Figure 2. Only 4a out of four lineages exposed to the three-compound combination adapted to a 32-270 
fold higher MIC of 256 µg/ml), whereas the other three i.e. 4b, 4c and 4d remained at 4-, 8- and 8-271 
fold higher MIC (32 and 64 µg/ml, respectively) as shown in Figure 2. 272 
 273 
3.2 Re-growth of adapted lineages in presence of compound. 274 
All adapted lineages were revived from frozen stocks and re-grown at the compound concentration 275 
that they were adapted to. All four 1-adapted lineages, 3c, and 4a (Table 2) were able to re-grow at 276 
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the concentration that they were adapted to, as opposed to the remaining lineages. The 2-adapted 277 
lineages were only able to re-grow at ¼ of the MIC that they were originally adapted to, and similar 278 
results were seen for 3a and 3b as well as for 4c. Lineages 3d, 4b and 4d were all able to re-grow at 279 
½ of the MIC that they were originally adapted to (Table 2). 280 
 281 
3.3 Assessment of resistance in adapted lineages. 282 
Stability of resistance was tested by determining MIC after five transfers, corresponding to 283 
approximately 35 generations, in absence of compound (Table 2). Lineage 2a had a MIC of 4 µg/ml 284 
when re-tested, despite being adapted to 64 µg/ml. Only one of five clones i.e. 2d-4 had a high MIC 285 
of 64 µg/ml (Table 3) while for all the other clones MIC was comparable to wt MIC, i.e 4-16 µg/ml. 286 
2a and 2d and selected derived clones were whole-genome sequenced, as they were found to be the 287 
most susceptible and resistant, respectively.  288 
 289 
In the 1-adapted lineages the measured MIC was equivalent to a 32-fold higher MIC than the wt 290 
MIC (128 µg/ml) or even higher (256-512 µg/ml). Also, the high MIC was maintained in clones 291 
isolated from three out of four lineages, except for 1b-4 (Table 3). The lineages with the highest and 292 
lowest MIC values, respectively, 1a and 1c, were whole-genome sequenced as were two clones for 293 
each lineage.  294 
 295 
MIC for 3c, originally evolved to a 16-fold higher MIC of 128 µg/ml, remained high (64-128 296 
µg/ml) after re-growth in presence of compound and upon five subsequent re-inoculations in 297 
absence of compound. In the five isolated clones, the measured MIC varied from a lower limit equal 298 
to the wt MIC (8-16 µg/ml) to an upper limit of 64 µg/ml (Table 3).  299 
MIC for 4a (adapted to 256 µg/ml) was 32-128 µg/ml after re-growth in presence of compound, and 300 
reached 16-32 µg/ml after five subsequent re-inoculations in absence of compound. In the isolated 301 
clones, a MIC range up to 128 µg/ml was found only in two out of 20 clones (Table 3). These 302 
results indicate that the resistance trait decreased in absence of compound, even though 3c and 4a 303 
previously adapted to a 16-fold higher MIC of 128 µg/ml and a 32-fold higher MIC of 256 µg/ml, 304 
respectively).  305 
Lineages 3c and 4a were whole-genome sequenced as representatives of resistant lineages, along 306 
with two clones from each of them. 307 
 308 
Lineage 4b (adapted to a 4-fold higher MIC of 32 µg/ml) and 4c and 4d (adapted to an 8-fold higher 309 
MIC of 64 µg/ml) as well as clones derived from these lineages displayed generally higher MIC 310 
than 3a (adapted to an 8-fold higher MIC of 64 µg/ml), 3b and 3d (both adapted to a 4-fold higher 311 
MIC of 32 µg/ml). In fact, 4c and 4d had MIC of 16-64 and 32 µg/ml, respectively, when grown in 312 
presence of compound (Table 2). In the clones isolated from such lineages, MIC values were 313 
between 8 and 128 µg/ml, while in all clones, isolated from 4a, 4b and 4d, MIC values did not 314 
exceed the wt MIC (8-16 µg/ml). Given these data, 4b and 3d were whole-genome sequenced as 315 
representatives of susceptible lineages. 316 
 317 
Cross resistance was assessed in the lineages where resistance persisted to the highest degree (1a, 318 
3c, 4a, 2d). MIC of peptidomimetics displaying structural variations as compared to 1 was also 319 
assessed (Table 4). Resistance was maintained toward compounds 5 and 6. It is noticeable that the 320 
lipidated compound 7 retained almost full activity against 1a (MIC was 16 µg/ml as compared to 4-321 
8 µg/ml in the wild type) but not against the other resistant lineages. Compound 2 retained full 322 
activity against 1a and 3c, but not against 4a. This was also reflected in the MIC values of 2 in 323 
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combination with 1. In lineage 1a, resistance was retained toward 1 and 3. The two-compound 324 
combinations seemed to be less effective than the combination of three compounds. Compound 2 325 
alone showed the best activity on resistant lineages adapted to the other two compounds.   326 
 327 
3.4 Whole-genome sequencing. 328 
 329 
The wild type E. coli ATCC 25922 genome was assembled into 156 contigs with 89× coverage. A 330 
fully closed genome is available at NCBI; however, we chose to genome-sequence the actual strain 331 
we worked with. The wild type genome showed 30 variants with frequencies above 60%, with 332 
fourteen of them occurring in coding regions (Supplementary Table 2), as compared to the fully 333 
closed genome. This number indicated that comparison of the adapted strains to the de novo 334 
sequenced wild type was justified. 335 
 336 
Sequences from the adapted lineages and clones were mapped to the wild type contigs, and an 337 
average number of 26 variants per genome with a frequency above 60% were found. Variants in 338 
coding regions were on average 14. Among these, an average of 6 variants caused an amino acid 339 
change in proteins. In non-exposed lineages, we found an average number of 24 variants per 340 
genome with a frequency above 60%. Among these, an average of 14 were located in coding 341 
regions, and 5 variants caused amino acid changes in encoded proteins (Table 5; Supplementary 342 
Table 1).  343 
 344 
Deletions in the CDP-glycerophosphotransferase (CDP-glycerol: N-acetyl-β-D-mannosaminyl-1,4-345 
N-acetyl-D-glucosaminyldiphosphoundecaprenyl glycerophosphotransferase) were seen in 6 out of 346 
8 exposed lineages and in 11 clones. Interestingly, deletions were seen in clone 3c-4, but not in its 347 
parent lineage (3c). The deletions occurred in different regions of the same protein (Figure 3). 348 
However, there was no pattern between variant type, peptide and lineage, except for 2d, where the 349 
same deletion type was found both in the community and in the clones. 350 
 351 
Lineages that, based on MIC assessment, showed the highest level of resistance (the 1-adapted 352 
lineages as well as 3c and 4a) did not share the same variant pattern. In fact, 1a had a deletion in the 353 
genes encoding CDP-glycerophosphotransferase while its two isolated clones also showed a 354 
mutation in the outer-membrane protein assembly factor YaeT precursor. By contrast 1c displayed a 355 
mutation in three different proteins besides a deletion in the CDP-glycerophosphotransferase that 356 
was different from the one acquired by lineage a. In 4a, the highest number of variants was found 357 
(55 with a frequency above 60%). Among these, ten variants corresponded to non-synonymous 358 
mutations in coding regions, and three of these may be suggested to be involved in the resistance 359 
genotype: a deletion in the CDP-glycerophosphotransferase (present in 3d-4, 1a-1 and 1a-5), and 360 
mutations in the respiratory nitrate reductase δ chain and in the GTP pyrophosphokinase 361 
bifunctional (p)ppGpp synthase/hydrolase SpoT, respectively. 362 
 363 
In 2a, which was less resistant than the other three lineages, a mutation in the diguanylate cyclase 364 
domain protein and one in the Zinc ABC transporter ZnuA were found in both the lineage 365 
community and in the derived clones. These mutations did not appear in any of the other adapted 366 
lineages. Also, this lineage, and its derived clones, did not show any deletion in the CDP-367 
glycerophosphotransferase. By contrast, in 2d a deletion in the same region of the CDP-368 
glycerophosphotransferase was present in both the lineage community and in the derived clones. 369 
Some of the mutations found in 3d-4, such as the ones in the CDP-glycerophosphotransferase, 370 
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respiratory nitrate reductase δ chain and GTP pyrophosphokinase, were also present in 4a and 4a-1. 371 
A mutation in the phage major capsid protein was found in both 3d and 4b-1.   372 
 373 
The mutational events, common to both adapted and non-exposed lineages, are shown in 374 
Supplementary Table 1. A mutation in the YeeV toxin protein arose in one exposed lineage and two 375 
clones (3c, 3c-1 and 4a-1). A different mutation in the same protein was seen in non-exposed clone 376 
0a-2. Interestingly, none of the 3-adapted lineages and clones had a mutation in the 377 
dihydrolipoamide acetyltransferase.  378 
 379 
A few mutational events were typical for the non-exposed lineages, such as mutations in the LysR 380 
transcription regulator LrhA, the mannose-specific adesin FimH, the phosphatase CheZ, involved in 381 
chemotaxis response and the arginine pathway regulatory protein ArgR2C (Supplementary Table 382 
1). 383 
 384 
3.5 Measurement of Zeta potential.  385 
 386 
The impact of the deletion in the CDP-glycerophosphotransferase gene on the resistance phenotype 387 
was assessed by measuring the Zeta potential of selected adapted lineages and clones. Average 388 
values for 3c and 1a-1 were –33 mV and –28 mV, respectively, both significantly higher than that 389 
found for the wild type (–48 mV).  390 
 391 
4 Discussion 392 
 393 
E. coli adapted readily to the peptidomimetic H-[Lys-βNSpe-hArg-βNSpe]3-NH2 (1) and the AMP 394 
novicidin (2). Indeed most of the lineages became resistant during the course of the adaptive 395 
evolution experiment. In contrast, resistance did not readily develop toward the P9-4 peptide (3), 396 
which differs from the other two compounds by displaying an arginine-tryptophan (RW) motif 397 
twice. This motif has been shown to increase the interaction of AMPs with membranes. In fact, for 398 
short peptides (6-12 residues) the presence of RW motifs has been highlighted as promoting 399 
membrane interactions, since arginine preferentially forms bidentate hydrogen bonds with the polar 400 
headgroups of phosphatidylglycerol, while tryptophan traverse the membrane by intercalation (Liu 401 
et al., 2007). Hence, the delayed resistance development may be related to the strongly membrane-402 
disruptive mode of action that also confers some concomitant toxicity toward human cells. In 403 
addition, RW motifs preferentially induce inter-peptide rather than intra-peptide interactions (Liu et 404 
al., 2007). This latter feature may increase the number of molecular targets in the bacterial cell 405 
membrane, thereby delaying resistance development.  406 
Common mutations were identified in the gene CDP-glycerophosphotransferase encoding an 407 
enzyme consisting of 1266 amino acids. Single-nucleotide deletions were found in three different 408 
regions of this gene (Figure 3). A deletion (found in the genomes of 1a, 3c-1, 3d and 3d-1) was 409 
located in a region encoding the tetratricopeptide (TPR) domain, which is a putative protein-binding 410 
surface. A second deletion type, found in the genomes of 1c, 1c-1, 2d, 2d-1 and 2d-4, had occurred 411 
in a domain putatively involved in outer membrane biosynthesis, as previously shown in Klebsiella 412 
pneumoniae (Frirdich et al., 2004). The third deletion type (present in 1a-1, 1a-5, 3d-4, 4a and the 413 
derived clones as well as in 4b and the derived clone 4b-1), was in a domain functionally related to 414 
cell wall biogenesis as well as lipid transport and metabolism. The second and third deletion types 415 
were located in the region responsible for the phosphotransferase activity thus inferring a putative 416 
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resistance mechanism based on deficient introduction of negative charge to the membrane. Such 417 
mutations are likely to inhibit phosphorylation, thereby reducing the negative charge of the 418 
membrane, and limiting the interaction with positively charged AMPs. We hypothesized that 419 
lineages and clones which acquired a deletion that decreased the phosphotransferase activity would 420 
possess less negative membranes. Indeed, higher zeta potential (–28 mV) was measured for clone 421 
1a-1 as compared to both wild type (–48 mV) and 3c (–33 mV). The latter also possessed 422 
significantly increased surface charge as compared to the wild type, indicating that it had acquired a 423 
surface charge modification arising from deficiencies in at least one other membrane-related 424 
maintenance system. This result suggests that for clone 1a-1 the mutation in CDP-425 
glycerophosphotransferase may affect the bacterial surface charge resulting in a less negative 426 
membrane. This mechanism seems to constitute a novel variation as compared to the known 427 
strategies of limiting the attraction of cationic compounds (Band and Weiss, 2015). Occurrence of 428 
the same variant across lineages exposed to distinct compounds appears to be linked to the similar 429 
nature of the antibacterial agents giving rise to the selection pressure (Band and Weiss, 2015). It is 430 
unclear whether the distinct deletion types confer different levels of resistance. However, 1c 431 
exhibited the same deletion in the CDP-glycerophosphotransferase as also found in 2d, and for both 432 
the MIC values suggest that resistance was probably induced by activation of preexisting adaptive 433 
systems, unlike the other 1-adapted lineages, where resistance was maintained. This shows that 434 
diversification into different genotypes occurs both within lineages adapted to the same compound 435 
and across lineages exposed to different compounds.   436 
Despite the heterogeneity, the variants can be divided into four distinct groups, which represent 437 
genotypes that have followed parallel evolutionary trajectories. The deletion in the CDP-438 
glycerophosphotransferase was not present in 2a, which instead had acquired mutations in the 439 
diguanylate cyclase domain protein and in the periplasmic zinc transporter ZnuA. The former seems 440 
to be involved in phosphorylation (like the CDP-glycerophosphotransferase), the latter in zinc 441 
uptake (Hantke, 2005; Ammendola et al., 2007). A mutation in the zinc uptake system protein 442 
ZnuA may be related to a known mechanism of resistance based on peptide degradation by zinc-443 
dependent metalloproteases (Kooi and Sokol, 2009). 444 
 445 
Three genomes (3d-4, 4a and 4a-1) had acquired mutations in the respiratory nitrate reductase δ 446 
chain, in the GTP pyrophosphokinase, alongside a deletion in the same region of the CDP-447 
glycerophosphotransferase. The respiratory nitrate reductase δ chain is essential for assembly of the 448 
whole enzyme; hence, a mutation in this subunit may affect the overall function of the protein if the 449 
assembly itself is compromised. Yet, the consequence of these mutations on resistance development 450 
remains unclear.  451 
 452 
Lineage 3c, the most resistant among the 3-adapted lineages, did not have a deletion in the CDP-453 
glycerophosphotransferase. Remarkably, despite the absence of a deletion in the CDP-454 
glycerophosphotransferase, this specific lineage developed stable resistance. In contrast, 2a, also 455 
lacking this deletion, was less resistant than 3c. These findings may be related to the different 456 
variant patterns that the lineages have acquired in presence of different compounds. However, the 457 
deletion in the CDP-glycerophosphotransferase was present in 3c-4, inferring that there has been 458 
more than one mutational trajectory within the same lineage community exposed to the same 459 
compound. In fact, this selected clone may merely represent a rarely occurring genotype in the 460 
lineage population. Nevertheless, 3c may represent a special case where the previously acquired 461 
mutations were lost in the next generations, because they were deleterious (Török et al., 2012). 462 
I  r vi
w




Potential loss of the mutations in the CDP-glycerophosphotransferase may be responsible for the 463 
prolonged period needed to reach adaptation to the highest concentration of exposure (128 µg/ml).  464 
 465 
In conclusion, the four main mutational trajectories may be summarized as: a first one can be 466 
identified in the acquisition of a deletion in the CDP-glycerophosphotransferase, a second one in the 467 
diguanylate cyclase domain protein and in the periplasmic zinc transporter protein ZnuA, a third 468 
one had no deletion in the CDP-glycerophosphotransferase, while a fourth trajectory resulted in 469 
mutations in the respiratory nitrate reductase δ chain, in the GTP pyrophosphokinase, alongside a 470 
deletion in the CDP-glycerophosphotransferase.     471 
 472 
The presence of the short peptide P9-4 in the combination appears to have slowed down the 473 
resistance development in three out of four lineages exposed to the combination. Nevertheless, the 474 
simultaneous exposure to three compounds may account for the decreased rate of resistance 475 
development, as inferred by the work of Pirrone et al. (2011). However, it has been highlighted  that 476 
in clinical studies of Gram-negative infections there was no difference in emergence of resistance 477 
during combination therapy versus monotherapy (Tamma et al., 2012). 478 
 479 
For lineage 4a resistance development was faster than for the other three 4-adapted lineages. 480 
However, despite adaptation to a 32-fold higher MIC of 256 µg/ml, this lineage proved incapable of 481 
retaining a high level of resistance as opposed to 1a, 1b and 1d. MIC results performed on adapted 482 
lineages and derived clones may overall indicate that for the three 1-adapted lineages as well as for 483 
3c and 4a, resistance was relatively stable, and hence arises from genetic mutations, while for the 484 
others resistance may be a phenotypic switch trait, caused by inducible preexisting adaptive 485 
systems. In fact, exposure to sub-MIC concentrations may lead to upregulation of efflux pumps or 486 
simply decreased membrane permeability due to LPS modification with additional fatty acid chains 487 
(Nizet, 2006).  488 
Overall, the resistant genotypes had acquired a few distinct but non-identical mutations that appear 489 
to be correlated to the mechanism of the evolved resistance.  490 
We conclude that mutations in CDP-glycerophosphotransferase may be a prime contributing factor 491 
in the adaptation to the investigated compounds. On the other hand, the zeta potential measurement 492 
is not an exhaustive method for confirming this hypothesis. We envision that only the construction 493 
of wild type mutants with deletions in the CDP-glycerophosphotransferase would unequivocally 494 
confirm whether this indeed is the primary cause of the observed resistant phenotype. 495 
It is not known whether independent mutations or rather the interplay between different cooperative 496 
mutations is responsible for resistance. As pointed out by Martinez and Baquero (2000), the 497 
emergence of independent or cooperative mutations depends on the specific bacterium-compound 498 
interaction. Also, it is known that a change of a single residue in an encoded protein may not 499 
interfere with its activity, unless the change occurs in the active site of an enzyme or in a residue 500 
that is involved in folding of the protein (Studer et al., 2013).  501 
The three antibacterial compounds investigated for their potential risk of inducing resistance were 502 
selected to represent distinct structural differences, and thus comprised a non-helical 12-residue 503 
peptidomimetic H-(Lys-βNphe-hArg-βNphe)3-NH2 (denoted 1), with an alternating design of 504 
cationic Lys/hArg and aromatic peptoid residues, a typical 18-mer α-helical highly cationic AMP 505 
(i.e. novicidin also denoted 2) as well as a very short 9-residue Arg/Trp-rich AMP (i.e. P9-4 also 506 
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denoted 3). Interestingly, lineage 1a exhibited cross resistance to both peptidomimetics 6 and 8 (Ac-507 
[Lys-βNphe]8-NH2 and Ac-[hArg-βNSpe]6-NH2) displaying only Lys or hArg residues, 508 
respectively, together with aromatic peptoid units, while susceptibility to the lipidated Lys-based 509 
analogue 7 was almost fully retained inferring that this structural modification most likely is 510 
associated with an altered mode of action. Nevertheless, this seems not just to be correlated with an 511 
increased overall lipophilicity of compound 7, since cross resistance to the hydrophobic analogue 5 512 
had evolved also. Analogue 5 resembles compound 1 with respect to cationicity, but contains 513 
additional α-methyl groups in the peptoid side chains as well as a significant content of aliphatic 514 
cyclohexyl peptoid side chains, which collectively confer similar enhanced hydrophobicity as the 515 
single fatty acid in compound 7. Noticeably, the structurally most different compounds, 1 and 2, 516 
displayed less and no cross resistance, respectively. Somewhat surprisingly the combination of three 517 
and the 1+2 pair displayed similar activity against all resistant strains tested, whereas other two-518 
compound combinations were less effective than the individual compounds. Compound 2 alone in 519 
fact showed unchanged activity on resistant lineages adapted to other compounds inferring that its 520 
killing mechanism appears to deviate significantly from those of 1 and 3.   521 
We show that resistance development toward a combination of three AMPs was slower than to two 522 
of the three compounds when used alone. However, resistance to one of the peptides (P9-4) alone 523 
was surprisingly difficult to evolve. These findings indicate that resistance development is 524 
compound-dependent rather than combination-dependent. We propose that constrained evolutionary 525 
resistance-inducing trajectories are compound-dependent. Also, it is suggested that the influence of 526 
certain mutations can be explained, as they occurred in lineages upon exposure to different 527 
compounds. Our results infer that P9-4 may constitute a potential lead for a future drug candidate, 528 
and we encourage early-stage investigation of resistance development for all promising novel 529 
antibacterial compounds. In addition, the issue of the potential risk of cross-resistance seems to be 530 
quite complex as no clear-cut conclusions can be made from this limited study. However, more 531 
detailed studies comprising a larger number of AMPs are warranted in order to assess to which 532 
degree activity of other subclasses of AMPs will be compromised by resistance development to a 533 
single AMP or to a combination of antibacterials.   534 
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Table 1: MIC of the compounds used in the present study against E. coli ATCC 25922.  737 
 738 
















1 (H-[Lys-βNSpe-hArg-βNSpe]3-NH2), 2 (novicidin), 3 (P9-4), 4 (1+2+3), 5 (Ac-[hArg-βNSce-Lys-739 























Table 2: Fold change in adapted lineages as compared to wt MIC of the compounds used in the 757 
adaptation. 758 
  
Fold increase as compared to wt MIC 
 
Lineage At the end of ALE At re-growth upon 







in absence of 
compound 
1a 16-32 16-32 64 16-32 
1b 16-32 16-32 64 16 
1c 16-32 16-32 64 32 
1d 16-32 16-32 32-64 32 
     
2a * 4-16 1-4 1 1 
2b * 16-64 4-16 1 2-4 
2c* 16-64 4-16 2-4 1-2 
2d* 16-64 4-16 4-16 2-8 
     
3a * 4-8                1-2 1 1 
3b * 2-4 1 1 1 
3c  8-16 8-16 8 4-8 
3d * 2-4 1-2 1 1 
     
4a  32 32 4-16 2-4 
4b * 4 2 1-2 1-2 
4c * 8 2 2-8 2 
4d * 8 4 4 2 
 759 
Note: the fold increase presented in the first two columns refers to MIC values reported in Table 1. The 760 
actual concentration of adaptation is reported in Figure 2. *Lineages that did not grow at the concentration of 761 
adaptation and therefore were grown in lower concentration. Lineages in bold were whole-genome 762 


















Table 3: Fold change in MIC of the compounds in five clones isolated from each adapted lineage.  775 
 776 
 Fold change in MIC of the respective compound for each clone (1-5) 
Lineage 1 2 3 4 5 
1a 32-64 32-64 32-64 32-64 32 
1b 16 16 16 1 16 
1c 2 4 2-8 4-8 4-8 
1d 32 8-32 16-32 32 64 
      
2a 1 1 1 1 1 
2b 1 1 1 1 1 
2c 1 1 1 1 1 
2d 1 1 1 4-16 1 
      
3a 1 1 1 1 1 
3b 1 1 1 1 1 
3c 4 2-4 4 2-4 4 
3d 1 1 1 1 1 
      
4a 2-4 4 4 4 2-4 
4b 1-2 2 1-4 2-4 1-2 
4c 2 1-2 1-8 1 1 
4d 1 2-16 2-4 8-16 2 
 777 
All clones were tested against the respective compound used for adaptation. Fold changes in bold relate to 778 




























Table 4: Cross resistance in selected resistant lineages. 801 
 802 
Compound  Fold change in MIC (µg/ml) in adapted lineages 
  1a 3c 2d 4a 
1  32-64 16 4-8 64-128 
2  1 1 4-16 2-8 
3  2-4 8-16 2-4 8-16 





















1 + 2  1 4 2-4 8 
1 + 3  8 16 4 32 
2 + 3  2 4-8 4-8 8 
 803 
1 (H-[Lys-βNSpe-hArg-βNSpe]3-NH2), 2 (novicidin), 3 (P9-4), 4 (1+2+3), 5 (Ac-[hArg-βNSce-Lys-804 
βNSpe]3-NH2), 6 (Ac-[Lys-βNphe]8-NH2), 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2).  805 
  806 
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Table 5: Single-nucleotide variants (frequency >60%) causing amino acid change in adapted lineages and respective clones. In italic: variant causing 807 
synonymous mutations. 808 
 809 
    Mutations in adapted lineages and clones 
 1  2  3  4 
































CDP-glycerophosphotransferase  x x x x x      x x x    x x x x  x x x x x  
Respiratory nitrate reductase δ 
chain  
                   x  x x     
GTP pyrophosphokinase                     x  x x     
Unsaturated fatty acid biosynthesis  
repressor FabR2C TetR  
                        x   
Diguanylate cyclase         x x x                  
Outer membrane protein assembly 
factor YaeT precursor  
 x x                         
Uncharacterized Yrbk             x                
S-formylglutathione hydrolase              x               
Transcriptional activator  
of maltose regulon 2C MalT  
            x               
Zinc ABC transporter ZnuA        x x x                  
Phage major capsid protein                  x        x  
T1SS secreted agglutinin RTX          x                 x x 
Mobile element protein         x  x                 
Antirestriction protein klcA     x    x   x x           x    
Exopolygalacturonate lyase           x x x               
FecD (Iron transport protein)     x                     x  
Glutamate decarboxylase                 x  x    x     
Ferredoxin reductase                    x        
Periplasmic binding protein                         x   
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We show lineages 1a and 1c and clones 1a-1, 1a-5, 1c-1, 1c-5 for H-[Lys-βNSpe-hArg-βNSpe]3-NH2, lineages 2a and 2d and clones 2a-1, 2a-3, 2d-1, 2d-4 for novicidin, 811 
lineages 3c and 3d and clones 3c-1, 3c-4, 3d-1, 3d-4 for P9-4, lineages 4a and 4b and clones 4a-1, 4a-2, 4b-1, 4b-4 for the combination. We report only variants that were not 812 








12 Figure legends 814 
 815 
Figure 1: Structure of the peptidomimetics used in the present study. From the top left, 816 
clockwise: compound 1 (H-[Lys-βNSpe-hArg-βNSpe]3-NH2) 5 (Ac-[hArg-βNSce-Lys-βNSpe]3-817 
NH2) 6 (Ac-[Lys-βNphe]8-NH2) 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2).  818 
 819 
Figure 2: Adaptive laboratory evolution of E. coli to the single compounds and the 820 
combination. Four independent lineages (black line: lineage a, red line: lineage b, blue line: lineage 821 
c, green line: lineage d) were adapted for each treatment: H-[Lys-βNSpe-hArg-βNSpe]3-NH2 822 
(compound 1), novicidin (2), P9-4 (3), and the combination of the three compounds (4). 823 
 824 
Figure 3: Location of the three deletion types in the gene encoding for the CDP-825 
glycerophosphotransferase. The precise location of the deletions is marked with a purple bar. 826 
The deletions were found in a region encoding for the TPR domain (yellow) and in two distinct 827 
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Supplementary Table 1: Single nucleotide variants (frequency >60%) causing amino acid change in both adapted and non-exposed lineages. 
 
 Adapted lineages and clones   






















































                          x     x x x    
phosphatase CheZ                            x  x    x  x 
Arginine pathway  
regulatory protein 
ArgR2C 




                         x     x x x    
                                     
YeeV toxin protein              x x      x       x          
Mobile element 
protein  
x   x x x x  x x  x x x  x x  x x   x x x x x x x x x x x  x x 
DNA repair protein 
RadC  
x x x  x x x x x x x x x x x x x x x x x x x  x x x x x x x x x x x x 
Dihydrolipoamide  
acetyltransferase  
x x    x x x x x  x   x  x  x x x x x x     x x  x x   x 
Membrane protein 
b2001 
    x       x       x         x         
BigB  x                         x          
Uncharacterized 
YkfH 
x x x x x x x x x x x x x x x x x x x x x x x x  x x x x x x x x x x x x 
 
 3 
Variants typical of non-exposed lineages (0) are shown in the upper part of the table. In non-exposed lineages, 0a, 0b and respective clones were transferred 
until the adaptation experiment was ended while lineages 0c, 0d and respective clones were transferred until the first adaptation to 32× was completed. Single 
nucleotide variants detected both in adapted and in non-exposed lineages and clones are shown in the lower part of the table. 
 
Supplementary Table 2: Single nucleotide variants (frequency >60%) occurring in coding regions of the wild type genome used in the present study, as 
compared to the reference strain Escherichia coli ATCC 25922.  
 
Gene product Number of variants in coding regions 
LPS-assembly protein lptD 1 
Rhs element Vgr family protein 3 
Phage major capsid E family protein 1 
deoR C term sensor domain protein 2 
Glycosyl transferase 21 family protein 1 
Integrase core domain protein 1 
Putative membrane protein 1 
Putative entS/YbdA MF S transporter 1 
Propionate CoA ligase 1 





































demand& for& discovery& and& development& of& novel& antimicrobial& compounds& and& treatment&
strategies.& In& the& last& two& decades,& antimicrobial& peptides& (AMPs)& have& been& considered& as&
potential& novel& antibiotics& due& to& the& lack& of& widespread& coGevolution& of& resistance& in& nature&
(Ulvatne,&2003;& Zaiou,&2007).& Initially,& emergence&of& resistance& toward&AMPs&was&assumed& to&be&
low&due& to& their& rapid&bactericidal&activity& (Wimley&and&Hristova,&2011;&Fox,&2013).&Nevertheless,&
development& of& resistance& to& AMPs& has& been& raised& as& a& potential& risk& as& general& resistance&
mechanisms&might& compromise& the& innate& immune& defense& in& humans& (Bell& and& Gouyon,& 2003;&
Perron& et& al.,& 2006).& Resistance& is& a& natural& phenomenon& that& depends& on& the& environmental&
stimuli,&and&e.g.&stress&induced&by&AMPs&under&laboratory&conditions&may&exert&a&selection&pressure&
that&confers&bacterial&adaptive&resistance&(Hong&et&al.,&2016).&&
By& using& an& adaptive& laboratory& evolution& approach,& resistant&E.# coli& lineages,& exhibiting&
substantially& increased& minimal& inhibitory& concentrations& (MICs)& toward& AMPs& and&




to& investigate& the&potential&of& such& crossGresistance&as& it& represents& a&possible& risk& for& any&novel&
antibacterial& compound.& Interestingly,&Baym&et&al.,& (2016)& recently& reported& that& inversion&of& the&
selective&advantage&of&resistance&could&turn&a&resistant&population&susceptible&again.&Such&inversion&
of& the&selective&advantage& is& triggered&by&suppressive&drug& interactions.& In& fact,& resistance& to& the&
first& applied& drug& can& increase& the& sensitivity& to& a& second& applied& drug& (Imamovic& and& Sommer,&
2013).& The& latter& creates& a& concentration& regime& that& inhibits& the& growth& of& resistant& bacteria,&
hence& selecting& for& the& sensitive& part& of& the& population& (Baym& et& al.,& 2016).& Based& on& these&
observations,&we&hypothesized&that&suppressive&drug&interactions&can&select&against&AMPGresistant&
mutants,&hence&inducing&susceptibility&in&a&resistant&population.&
CrossGresistance& and& susceptibility& patterns& were& difficult& to& explain& when& only& a& few&
compounds& were& included& in& the& studies& (HeinGKristensen& et& al.,& 2013;& Citterio& et& al.,& 2016,&
submitted).&Hence,&the&present&purpose&was&to&assess&whether&previously&evolved&AMPGresistant&E.#
coli&clones&were&resistant&or&susceptible&to&a&structurally&more&diverse&range&of&compounds.&Thus&
we& selected& an& array& of& synthetic& AMPs& and& peptidomimetics& for& an& extended& study& of& crossG
resistance.& These& compounds& represent& a& variety& of& structural& features& such& as& length,&





AMPs&P9G4&and&novicidin& as&well& as&peptidomimetic&HG[LysGβNSpeGhArgGβNSpe]3GNH2& (HFG1002G2)&
individually& and& in& a& combination& of& all& three& compounds& were& examined& (Citterio& et& al.,& 2016,&
submitted).&From&wholeGgenome&sequence&analysis&of&these&AMPGadapted&clones,&we&identified&a&
novel& putative& distinct& mode& of& resistance& leading& to& an& overall& loss& of& negative& charge& of& the&
bacterial&membranes.&We&hypothesized&that&this&mechanism&of&resistance&was&genetically&encoded;&
hence& it& would& be& maintained& in& absence& of& the& selective& pressure& exerted& by& the& compound.&
Therefore& we& reGcultivated& highly& resistant& clones& in& absence& of& compound& and& investigated&


















































































highly& resistant& to& peptoids/AMPs& (Citterio& et& al.,& 2016,& submitted).& In& the& present& work& these&
clones& were& subGcultured& for& several& generations& in& order& to& determine&whether& resistance& was&
maintained&in&absence&of&a&selection&pressure&exerted&by&the&respective&compounds.&&A&reduction&in&
MIC& following& this& prolonged& culturing& in& absence& of& peptide& was& observed& for& six& out& of& the&
seventeen&original&clones&upon&the&5th&reGinoculation&(nGiv4,&P94Giii1,&P94Giii4,&cGi2,&cGii4,&cGiv4).&Only&









novicidin,& and& to& the& combination&of&all& three,&were&also& resistant& to& compounds&1,&3& (both&with&
intracellular&targets)&and&to&some&extent&to&compound&6&(LysGrich,&20&amino&acid&long,&membraneG
active).&By&contrast,&the&resistant&clones&were&sensitive&to&compounds&9&(ArgGrich;&with&IR&motifs;&8&


















the&combination&of&all& three&compounds,&were&also& resistant& to&compounds&1,&3& and&6& indicating&
that& they& share& a& common& mode& of& action,& and& thus& may& be& susceptible& to& similar& resistance&
mechanisms.&This&evolved&resistance&in&these&clones&comprises&compounds&1&and&3&that&both&have&
intracellular&activity&(Zhu&et&al.,&2007;&Lele&et&al.,&2013),&and&this&may&indicate&that&compound&6&also&
act& via&an& intracellular& target.&AMPs&with& intracellular&mechanisms&are&known& to&act& slower& than&
membraneGactive& AMPs& (Giacometti& et& al.,& 1998).& The& killing& mechanism& of& membraneGactive&
compounds& is&known&to& involve&multiple&possible& target&molecules,&while&AMPs&with& intracellular&
activity& are& more& likely& to& have& a& specific& target& (Jenssen& et& al.,& 2006).& Hence,& AMPGresistant&




evidence& supporting& that& crossGresistance& to& intracellularly& acting& compounds& occurs&more& likely&
than&to&membrane&active&ones,&as&our&study&infers.&Also,&proteolysis&and&extrusion&by&efflux&pumps&
are&very&common&means&by&which&bacteria&adapt&to&AMPs&(Band&and&Weiss,&2015;&Andersson&et&al.,&






clones& toward& compounds& 2& and& 9& (which& both& are& ArgGrich),& and& the& ultraGshort& lipidated&
compound&8&as&well&as&the&Lys/PheGrich&DGpeptide&11.&These&four&compounds&may&have&a&number&
of& targets& within& the& bacterial& membrane& that& allows& them& to& overcome& the& mechanisms& of&
resistance& acquired& by& all& tested& evolved& clones.& In& this& respect,& it&was& already& pointed& out& that&
small&differences& in&the&mechanism&of&action&might&conserve&the&activity&of&a&compound& in&AMPG
resistant&clones&(Macwana&and&Muriana,&2012).&Compound&2&is&a&12Gresidue&peptide;&compound&8&
is& LysGrich& (consisting& of& 4& amino& acids).& The& 8Gresidue& compound& 9& contains& IR& motifs& and&
represents&an&analogue&of&an&octapeptide&previously&highlighted&for&its&broadGspectrum&and&lack&of&
toxicity& (Ong& et& al.,& 2013;& Lau& et& al.,& 2015).& Hence,& these& structural& features& might& be& further&
explored&in&order&to&confirm&their&advantages&in&synthetic&drugs&for&which&resistance&development&
is&a&prominent&concern.&&
Other& experimentally& adapted& clones& could& be& tested& or,& even& better,& naturally&
resistant&bacteria&or&clinical&resistant&isolates.&&
This&study&highlights&that&AMPGresistant&mutants&become&susceptible&as&the&wildGtype&strain&upon&











































































































Arg/ProArich& 3! RRIRPRPPRLPRPRPRPANH2!!!! 17! +9! 3198.89! 4! 1.25!
Trp/ArgArich& 1! VRRFkWWWkFLRRANH2!!!!!










Lys/TrpArich& 10! (KW)4ANH2! 8! +5! 1844.68! 16! 8.67!
Trp/ArgArich& P9A4! KWRRWIRWLANH2!!! 9! +5! 1968.85! 8A16! 6.09!
ArgArich& 2! RRWRIVVIRVRRANH2!! 12! +7! 2462.26! 2A4! 1.21!
ArgArich;!β–sheet& 9! (IRIR)!2ANH2! 8! +5! 1664.53! 8! 4.8!
Lys/ArgArich! novicidin! KNLRRIIRKGIHIIKKYFANH2!!! 18! +9! 3322.09! 4A16! 3.01!
LysArich& 4! KWKLFKKVLKVLTTGANH2!! 15! +6! 2472.41! 4! 1.6!
LysArich& 5! KFLKKAKKFGKAFVKILANH2! 17! +8# 2905.80! 4! 1.3!
LysArich& 6! KWKSFIKKLTKKFLHSAKKFANH2! 20! +9! 3519.35! 2A4! 0.85!
LysArich;!lipidated& 8! PamAKKKKANH2!Lipidated!LysArich! 4! +4! 1224.22! 4A8! 4.9!
Lys/PheArich;!DApeptide& 11! AcAFKKLKKLFSKLFSFKANH2! 15! +6! 2614.58! 8! 3.05!
AlaArich& 7! ALWKTLLKKVLKAAAKANH2! 15! +6! 2465.45! 2A4! 1.21!
Polypeptide!with!fatty!acid!
chains! PMB! C55H96N160132H2SO4!




Achiral!peptoid!/!LysAhArg& HFA1002A2! HA(LysAβNpheAhArgAβNphe)3ANH2! 12! +7! ! 4A8! !
Lys/ArgArich+!Trp/ArgArich+!
Achiral!peptoid!/!LysAhArg!

















! ! &&&&&&&&&&&&&&&&5th&&&&&&&&&&&&&&&&&&&&&&&&&&&10th&&&&&&&&&&&&&&&&&&&&&&&&15th&& !






































P948iii1! 32864! 16! 16832! 16! 182!
P948iii3! 32864! 32! 16832! 32! 284!
P94Fiii4& 32! 16! 16! 8816! 1!
P94Fiii5& 32864! 32864! 16! 64! 488!
c8i1! 16832! 16! 8! 8816! 182!































wt## & nFiv4& cFi2& cFiv4& P94F
iii4&
P94Fiii5& HFFi5& HFFiii5& HFFiv5&
*& 8! ! 488! 284! 1.25! 8! 488! 16! 4! 32!
1& 8! ! 16! >16! 16! 0.581! 32! 64! 32! 64!
3& 4! ! 8816! 32! 16! 0.584! 16832! 32! 8832! 32!
6& 284! ! 16832! 32864! 8! 182! 8816! 284! 488! 2!
5& 4! ! 8816! 32! 284! 284! 8! 2! 284! 2!
PMB& 0.2580.5! ! 284! 16! 4! 2! 8! 16! 284! 16!
7& 284! ! 8! 8816! 2! 2! 488! 284! 284! 182!
4& 4! ! 8! 8! 2! 182! 8! 488! 4! 4!
10& 16! ! 182! 8! 2! 1! 2! 4! 284! 8!
2& 284! ! 0.581! 284! 288! 1! 284! 284! 4! 284!
8& 488! ! 2! 284! 182! 182! 2! 182! 1! 182!
11& 8! ! 284! 2! 284! 182! 284! 2! 182! 0.5!










































P948iii4! 1! 8!CDP! 8! 8!T1SS!secreted!
agglutinin!RTX!















HF8iii5! 1! ! 4! 8!CDP!
HF8iv5! 64! 8!CDP! 57! 8!CDP!
!
